0001058307 NextPlat Corp false --12-31 Q3 2024 63 0 0.0001 0.0001 3,333,333 3,333,333 0.0001 0.0001 50,000,000 50,000,000 18,993,146 18,993,146 18,724,596 18,724,596 250,000 4,166.67 0 0 0 0 0 18,993,146 30,000 12 3 14,000 30,000 26,000 2 false false false false Decrease related to book tax basis difference of intangible assets arising for the business acquisition of Outfitter. 10 year amortization period Under federal tax law, previously unidentified finite lived intangible assets recognized from a business combination have no tax basis and therefore are not amortized for tax purposes. This tax position created a book/tax basis difference at April 1, 2024, the date of the business combination transaction. Therefore, an approximate $0.1 million deferred tax liability was recorded at April 1, 2024 as a result of the book/tax basis difference for the finite lived intangible assets. 5 year amortization period 0001058307 2024-01-01 2024-09-30 0001058307 us-gaap:CommonStockMember 2024-01-01 2024-09-30 0001058307 us-gaap:WarrantMember 2024-01-01 2024-09-30 xbrli:shares 0001058307 2024-11-08 thunderdome:item iso4217:USD 0001058307 2024-09-30 0001058307 2023-12-31 iso4217:USD xbrli:shares 0001058307 us-gaap:ProductMember 2024-07-01 2024-09-30 0001058307 us-gaap:ProductMember 2023-07-01 2023-09-30 0001058307 us-gaap:ProductMember 2024-01-01 2024-09-30 0001058307 us-gaap:ProductMember 2023-01-01 2023-09-30 0001058307 us-gaap:ServiceMember 2024-07-01 2024-09-30 0001058307 us-gaap:ServiceMember 2023-07-01 2023-09-30 0001058307 us-gaap:ServiceMember 2024-01-01 2024-09-30 0001058307 us-gaap:ServiceMember 2023-01-01 2023-09-30 0001058307 2024-07-01 2024-09-30 0001058307 2023-07-01 2023-09-30 0001058307 2023-01-01 2023-09-30 0001058307 us-gaap:CommonStockMember 2023-12-31 0001058307 us-gaap:AdditionalPaidInCapitalMember 2023-12-31 0001058307 us-gaap:RetainedEarningsMember 2023-12-31 0001058307 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-12-31 0001058307 us-gaap:ParentMember 2023-12-31 0001058307 us-gaap:NoncontrollingInterestMember 2023-12-31 0001058307 us-gaap:CommonStockMember 2024-01-01 2024-03-31 0001058307 us-gaap:AdditionalPaidInCapitalMember 2024-01-01 2024-03-31 0001058307 us-gaap:RetainedEarningsMember 2024-01-01 2024-03-31 0001058307 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2024-01-01 2024-03-31 0001058307 us-gaap:ParentMember 2024-01-01 2024-03-31 0001058307 us-gaap:NoncontrollingInterestMember 2024-01-01 2024-03-31 0001058307 2024-01-01 2024-03-31 0001058307 us-gaap:CommonStockMember 2024-03-31 0001058307 us-gaap:AdditionalPaidInCapitalMember 2024-03-31 0001058307 us-gaap:RetainedEarningsMember 2024-03-31 0001058307 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2024-03-31 0001058307 us-gaap:ParentMember 2024-03-31 0001058307 us-gaap:NoncontrollingInterestMember 2024-03-31 0001058307 2024-03-31 0001058307 us-gaap:CommonStockMember 2024-04-01 2024-06-30 0001058307 us-gaap:AdditionalPaidInCapitalMember 2024-04-01 2024-06-30 0001058307 us-gaap:RetainedEarningsMember 2024-04-01 2024-06-30 0001058307 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2024-04-01 2024-06-30 0001058307 us-gaap:ParentMember 2024-04-01 2024-06-30 0001058307 us-gaap:NoncontrollingInterestMember 2024-04-01 2024-06-30 0001058307 2024-04-01 2024-06-30 0001058307 us-gaap:CommonStockMember 2024-06-30 0001058307 us-gaap:AdditionalPaidInCapitalMember 2024-06-30 0001058307 us-gaap:RetainedEarningsMember 2024-06-30 0001058307 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2024-06-30 0001058307 us-gaap:ParentMember 2024-06-30 0001058307 us-gaap:NoncontrollingInterestMember 2024-06-30 0001058307 2024-06-30 0001058307 us-gaap:CommonStockMember 2024-07-01 2024-09-30 0001058307 us-gaap:AdditionalPaidInCapitalMember 2024-07-01 2024-09-30 0001058307 us-gaap:RetainedEarningsMember 2024-07-01 2024-09-30 0001058307 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2024-07-01 2024-09-30 0001058307 us-gaap:ParentMember 2024-07-01 2024-09-30 0001058307 us-gaap:NoncontrollingInterestMember 2024-07-01 2024-09-30 0001058307 us-gaap:CommonStockMember 2024-09-30 0001058307 us-gaap:AdditionalPaidInCapitalMember 2024-09-30 0001058307 us-gaap:RetainedEarningsMember 2024-09-30 0001058307 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2024-09-30 0001058307 us-gaap:ParentMember 2024-09-30 0001058307 us-gaap:NoncontrollingInterestMember 2024-09-30 0001058307 us-gaap:CommonStockMember 2022-12-31 0001058307 us-gaap:AdditionalPaidInCapitalMember 2022-12-31 0001058307 us-gaap:RetainedEarningsMember 2022-12-31 0001058307 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2022-12-31 0001058307 us-gaap:ParentMember 2022-12-31 0001058307 us-gaap:NoncontrollingInterestMember 2022-12-31 0001058307 2022-12-31 0001058307 us-gaap:CommonStockMember 2023-01-01 2023-03-31 0001058307 us-gaap:AdditionalPaidInCapitalMember 2023-01-01 2023-03-31 0001058307 us-gaap:RetainedEarningsMember 2023-01-01 2023-03-31 0001058307 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-01-01 2023-03-31 0001058307 us-gaap:ParentMember 2023-01-01 2023-03-31 0001058307 us-gaap:NoncontrollingInterestMember 2023-01-01 2023-03-31 0001058307 2023-01-01 2023-03-31 0001058307 us-gaap:CommonStockMember 2023-03-31 0001058307 us-gaap:AdditionalPaidInCapitalMember 2023-03-31 0001058307 us-gaap:RetainedEarningsMember 2023-03-31 0001058307 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-03-31 0001058307 us-gaap:ParentMember 2023-03-31 0001058307 us-gaap:NoncontrollingInterestMember 2023-03-31 0001058307 2023-03-31 0001058307 us-gaap:CommonStockMember nxpl:April2023PrivatePlacementMember 2023-04-01 2023-06-30 0001058307 us-gaap:AdditionalPaidInCapitalMember nxpl:April2023PrivatePlacementMember 2023-04-01 2023-06-30 0001058307 us-gaap:RetainedEarningsMember nxpl:April2023PrivatePlacementMember 2023-04-01 2023-06-30 0001058307 us-gaap:AccumulatedOtherComprehensiveIncomeMember nxpl:April2023PrivatePlacementMember 2023-04-01 2023-06-30 0001058307 us-gaap:ParentMember nxpl:April2023PrivatePlacementMember 2023-04-01 2023-06-30 0001058307 us-gaap:NoncontrollingInterestMember nxpl:April2023PrivatePlacementMember 2023-04-01 2023-06-30 0001058307 nxpl:April2023PrivatePlacementMember 2023-04-01 2023-06-30 0001058307 us-gaap:CommonStockMember 2023-04-01 2023-06-30 0001058307 us-gaap:AdditionalPaidInCapitalMember 2023-04-01 2023-06-30 0001058307 us-gaap:RetainedEarningsMember 2023-04-01 2023-06-30 0001058307 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-04-01 2023-06-30 0001058307 us-gaap:ParentMember 2023-04-01 2023-06-30 0001058307 us-gaap:NoncontrollingInterestMember 2023-04-01 2023-06-30 0001058307 2023-04-01 2023-06-30 0001058307 us-gaap:CommonStockMember 2023-06-30 0001058307 us-gaap:AdditionalPaidInCapitalMember 2023-06-30 0001058307 us-gaap:RetainedEarningsMember 2023-06-30 0001058307 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-06-30 0001058307 us-gaap:ParentMember 2023-06-30 0001058307 us-gaap:NoncontrollingInterestMember 2023-06-30 0001058307 2023-06-30 0001058307 us-gaap:CommonStockMember 2023-07-01 2023-09-30 0001058307 us-gaap:AdditionalPaidInCapitalMember 2023-07-01 2023-09-30 0001058307 us-gaap:RetainedEarningsMember 2023-07-01 2023-09-30 0001058307 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-07-01 2023-09-30 0001058307 us-gaap:ParentMember 2023-07-01 2023-09-30 0001058307 us-gaap:NoncontrollingInterestMember 2023-07-01 2023-09-30 0001058307 us-gaap:CommonStockMember 2023-09-30 0001058307 us-gaap:AdditionalPaidInCapitalMember 2023-09-30 0001058307 us-gaap:RetainedEarningsMember 2023-09-30 0001058307 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-09-30 0001058307 us-gaap:ParentMember 2023-09-30 0001058307 us-gaap:NoncontrollingInterestMember 2023-09-30 0001058307 2023-09-30 0001058307 nxpl:EcommerceMember 2024-01-01 2024-09-30 0001058307 nxpl:EcommerceMember 2023-01-01 2023-09-30 0001058307 nxpl:HealthcareOperationsMember 2024-01-01 2024-09-30 0001058307 nxpl:HealthcareOperationsMember 2023-01-01 2023-09-30 0001058307 nxpl:ProgressiveCareMember 2024-01-01 2024-09-30 0001058307 nxpl:ProgressiveCareMember 2023-01-01 2023-09-30 0001058307 nxpl:OutfitterSatelliteIncMember 2024-01-01 2024-09-30 0001058307 nxpl:OutfitterSatelliteIncMember 2023-01-01 2023-09-30 xbrli:pure 0001058307 nxpl:OutfitterSatelliteIncMember 2024-04-01 0001058307 nxpl:ProgressiveCareMember nxpl:Pharmco901Member 2024-09-30 0001058307 nxpl:FloridaSunshineBrandsLLCMember 2023-12-06 0001058307 nxpl:OuterBrandsFSLLCMember nxpl:FloridaSunshineBrandsLLCMember 2023-12-06 0001058307 nxpl:ProgressiveCareMember 2023-07-01 0001058307 nxpl:ProgressiveCareMember nxpl:ConversionOfProgressiveCareCommonShareToNextplatCommonStockMember us-gaap:SubsequentEventMember 2024-10-01 0001058307 srt:MaximumMember 2024-09-30 0001058307 nxpl:ClosingRateMember 2024-09-30 0001058307 nxpl:QuarterlyAverageRateMember 2024-09-30 0001058307 nxpl:ClosingRateMember 2023-09-30 0001058307 nxpl:QuarterlyAverageRateMember 2023-09-30 0001058307 nxpl:ClosingRateMember 2023-12-31 0001058307 nxpl:YearlyAverageRateMember 2023-12-31 0001058307 nxpl:TerminationOfEmploymentThomasSeifertCFOMember us-gaap:SettledLitigationMember us-gaap:SubsequentEventMember 2024-10-15 2024-10-15 0001058307 nxpl:ProgressiveCareMember us-gaap:FairValueInputsLevel3Member 2023-07-01 0001058307 nxpl:OutfitterSatelliteIncMember us-gaap:FairValueInputsLevel3Member 2024-04-01 0001058307 nxpl:OutfitterSatelliteIncMember 2024-04-01 2024-04-01 0001058307 nxpl:OutfitterSatelliteIncMember 2024-04-01 0001058307 nxpl:OutfitterSatelliteIncMember us-gaap:TradeNamesMember 2024-04-01 0001058307 nxpl:OutfitterSatelliteIncMember us-gaap:CustomerListsMember 2024-04-01 utr:Y 0001058307 us-gaap:TradeNamesMember 2024-04-01 0001058307 us-gaap:CustomerListsMember 2024-04-01 0001058307 nxpl:OutfitterSatelliteIncMember us-gaap:ScenarioAdjustmentMember 2024-04-01 0001058307 nxpl:OutfitterSatelliteIncMember 2024-01-01 2024-01-01 0001058307 nxpl:OutfitterSatelliteIncMember us-gaap:MeasurementInputDiscountRateMember 2024-01-01 0001058307 nxpl:OutfitterSatelliteIncMember nxpl:MeasurementInputAssumedCapitalizationRateMember 2024-01-01 0001058307 nxpl:OutfitterSatelliteIncMember us-gaap:MeasurementInputLongTermRevenueGrowthRateMember 2024-01-01 0001058307 nxpl:OutfitterSatelliteIncMember nxpl:MeasurementInputAssumedRoyaltyRateMember 2024-01-01 0001058307 nxpl:OutfitterSatelliteIncMember nxpl:MeasurementInputAssumedTaxRateMember 2024-01-01 0001058307 nxpl:OutfitterSatelliteIncMember us-gaap:MeasurementInputRiskFreeInterestRateMember 2024-01-01 0001058307 nxpl:OutfitterSatelliteIncMember nxpl:MeasurementInputAssumedEquityRiskPremiumMember 2024-01-01 0001058307 nxpl:OutfitterSatelliteIncMember nxpl:MeasurementInputCompanySpecificRiskPremiumRateMember 2024-01-01 0001058307 nxpl:OutfitterSatelliteIncMember nxpl:MeasurementInputAssumedBetaMember 2024-01-01 0001058307 nxpl:EcommerceMember nxpl:EcommerceRevenueMember 2024-07-01 2024-09-30 0001058307 nxpl:EcommerceMember nxpl:HealthcareOperationsMember 2023-07-01 2023-09-30 0001058307 nxpl:PharmacyPrescriptionAndOtherRevenueNetOfPbmFeesMember nxpl:EcommerceRevenueMember 2024-07-01 2024-09-30 0001058307 nxpl:PharmacyPrescriptionAndOtherRevenueNetOfPbmFeesMember nxpl:HealthcareOperationsMember 2023-07-01 2023-09-30 0001058307 nxpl:PharmacyPrescriptionOtherRevenueAndEcommerceMember nxpl:EcommerceRevenueMember 2024-07-01 2024-09-30 0001058307 nxpl:PharmacyPrescriptionOtherRevenueAndEcommerceMember nxpl:HealthcareOperationsMember 2023-07-01 2023-09-30 0001058307 nxpl:Pharmacy340bContractMember nxpl:EcommerceRevenueMember 2024-07-01 2024-09-30 0001058307 nxpl:Pharmacy340bContractMember nxpl:HealthcareOperationsMember 2023-07-01 2023-09-30 0001058307 nxpl:EcommerceRevenueMember 2024-07-01 2024-09-30 0001058307 nxpl:HealthcareOperationsMember 2023-07-01 2023-09-30 0001058307 nxpl:EcommerceMember nxpl:EcommerceRevenueMember 2024-01-01 2024-09-30 0001058307 nxpl:EcommerceMember nxpl:HealthcareOperationsMember 2023-01-01 2023-09-30 0001058307 nxpl:PharmacyPrescriptionAndOtherRevenueNetOfPbmFeesMember nxpl:EcommerceRevenueMember 2024-01-01 2024-09-30 0001058307 nxpl:PharmacyPrescriptionAndOtherRevenueNetOfPbmFeesMember nxpl:HealthcareOperationsMember 2023-01-01 2023-09-30 0001058307 nxpl:PharmacyPrescriptionOtherRevenueAndEcommerceMember nxpl:EcommerceRevenueMember 2024-01-01 2024-09-30 0001058307 nxpl:PharmacyPrescriptionOtherRevenueAndEcommerceMember nxpl:HealthcareOperationsMember 2023-01-01 2023-09-30 0001058307 nxpl:Pharmacy340bContractMember nxpl:EcommerceRevenueMember 2024-01-01 2024-09-30 0001058307 nxpl:Pharmacy340bContractMember nxpl:HealthcareOperationsMember 2023-01-01 2023-09-30 0001058307 nxpl:EcommerceRevenueMember 2024-01-01 2024-09-30 0001058307 us-gaap:EmployeeStockOptionMember 2024-07-01 2024-09-30 0001058307 us-gaap:EmployeeStockOptionMember 2023-07-01 2023-09-30 0001058307 us-gaap:EmployeeStockOptionMember 2024-01-01 2024-09-30 0001058307 us-gaap:EmployeeStockOptionMember 2023-01-01 2023-09-30 0001058307 us-gaap:WarrantMember 2024-07-01 2024-09-30 0001058307 us-gaap:WarrantMember 2023-07-01 2023-09-30 0001058307 us-gaap:WarrantMember 2024-01-01 2024-09-30 0001058307 us-gaap:WarrantMember 2023-01-01 2023-09-30 0001058307 srt:MaximumMember 2024-01-01 2024-09-30 0001058307 2023-01-01 0001058307 nxpl:AppliquesMember 2024-09-30 0001058307 nxpl:AppliquesMember 2023-12-31 0001058307 us-gaap:BuildingMember 2024-09-30 0001058307 us-gaap:BuildingMember 2023-12-31 0001058307 us-gaap:VehiclesMember 2024-09-30 0001058307 us-gaap:VehiclesMember 2023-12-31 0001058307 nxpl:WebsiteDevelopmentMember 2024-09-30 0001058307 nxpl:WebsiteDevelopmentMember 2023-12-31 0001058307 us-gaap:FurnitureAndFixturesMember 2024-09-30 0001058307 us-gaap:FurnitureAndFixturesMember 2023-12-31 0001058307 us-gaap:LandMember 2024-09-30 0001058307 us-gaap:LandMember 2023-12-31 0001058307 us-gaap:LeaseholdImprovementsMember 2024-09-30 0001058307 us-gaap:LeaseholdImprovementsMember 2023-12-31 0001058307 us-gaap:ComputerEquipmentMember 2024-09-30 0001058307 us-gaap:ComputerEquipmentMember 2023-12-31 0001058307 nxpl:RentalEquipmentMember 2024-09-30 0001058307 nxpl:RentalEquipmentMember 2023-12-31 0001058307 us-gaap:ConstructionInProgressMember 2024-09-30 0001058307 us-gaap:ConstructionInProgressMember 2023-12-31 0001058307 us-gaap:MeasurementInputLongTermRevenueGrowthRateMember nxpl:HealthcareOperationsMember 2024-09-30 0001058307 nxpl:MeasurementInputWeightedAverageCostOfCapitalMember nxpl:HealthcareOperationsMember 2024-09-30 0001058307 nxpl:EcommerceOperationsMember 2023-12-31 0001058307 nxpl:HealthcareOperationsMember 2023-12-31 0001058307 nxpl:EcommerceOperationsMember 2024-01-01 2024-09-30 0001058307 nxpl:HealthcareOperationsMember 2024-01-01 2024-09-30 0001058307 nxpl:EcommerceOperationsMember 2024-09-30 0001058307 nxpl:HealthcareOperationsMember 2024-09-30 0001058307 us-gaap:TradeNamesMember 2024-09-30 0001058307 us-gaap:CustomerContractsMember 2024-09-30 0001058307 nxpl:PharmacyRecordsMember 2023-12-31 0001058307 us-gaap:TradeNamesMember 2023-12-31 0001058307 us-gaap:ComputerSoftwareIntangibleAssetMember 2023-12-31 0001058307 us-gaap:CustomerContractsMember 2023-12-31 0001058307 nxpl:EcommerceOperationsMember 2024-01-01 0001058307 nxpl:HealthcareOperationsMember 2024-01-01 0001058307 2024-01-01 0001058307 nxpl:MortgageNotePayableCommercialBankCollateralizedMember 2024-09-30 0001058307 nxpl:MortgageNotePayableCommercialBankCollateralizedMember 2023-12-31 0001058307 nxpl:NotePayableUncollateralizedMember 2024-09-30 0001058307 nxpl:NotePayableUncollateralizedMember 2023-12-31 0001058307 nxpl:NotePayableCollateralizedMember 2024-09-30 0001058307 nxpl:NotePayableCollateralizedMember 2023-12-31 0001058307 nxpl:InsurancePremiumFinancingMember 2024-09-30 0001058307 nxpl:InsurancePremiumFinancingMember 2023-12-31 0001058307 nxpl:ProgressiveCareMember nxpl:CollateralizedPromissoryNoteMember 2018-12-31 0001058307 nxpl:ProgressiveCareMember nxpl:CollateralizedPromissoryNoteMember 2018-01-01 2018-12-31 iso4217:GBP 0001058307 nxpl:CoronavirusLoansMember nxpl:HsbcUkBankPlcMember 2020-07-16 0001058307 nxpl:CoronavirusLoansMember nxpl:HsbcUkBankPlcMember 2020-07-16 2020-07-16 0001058307 nxpl:ProgressiveCareMember nxpl:NoteObligationForPharmacyEquipmentMember 2021-04-30 0001058307 nxpl:ProgressiveCareMember nxpl:NoteObligationForPharmacyEquipmentMember 2021-04-01 2021-04-30 0001058307 nxpl:ProgressiveCareMember nxpl:AmendedNoteObligationToPurchasePharmacyEquipmentMember 2024-09-30 0001058307 nxpl:ProgressiveCareMember nxpl:AmendedNoteObligationToPurchasePharmacyEquipmentMember 2023-12-31 0001058307 nxpl:ProgressiveCareMember nxpl:NoteObligationToPurchasePharmacyEquipmentMember 2022-07-31 0001058307 nxpl:ProgressiveCareMember nxpl:NoteObligationToPurchasePharmacyEquipmentMember 2022-07-01 2022-07-31 0001058307 nxpl:ProgressiveCareMember nxpl:NoteObligationForPharmacyEquipmentMember 2024-09-30 0001058307 nxpl:ProgressiveCareMember nxpl:NoteObligationForPharmacyEquipmentMember 2023-12-31 0001058307 nxpl:ProgressiveCareMember nxpl:NoteObligationForVehiclesMember 2022-09-30 0001058307 nxpl:ProgressiveCareMember nxpl:NoteObligationForVehiclesMember 2022-09-01 2022-09-30 0001058307 nxpl:ProgressiveCareMember nxpl:NoteObligationForVehiclesMember 2023-12-31 0001058307 nxpl:April2023PrivatePlacementMember 2023-04-05 2023-04-11 0001058307 nxpl:April2023PrivatePlacementMember 2023-04-11 0001058307 nxpl:PredecessorCompanyMember nxpl:DebtConversionAgreementMember 2022-08-30 0001058307 nxpl:SecuredConvertiblePromissoryNoteMember nxpl:IliadMember nxpl:CeoAndBoardMemberMember 2022-09-02 2022-09-02 0001058307 nxpl:SecuredConvertiblePromissoryNoteMember nxpl:IliadMember 2022-09-02 2022-09-02 0001058307 nxpl:SecuredConvertiblePromissoryNoteMember nxpl:IliadMember srt:ChiefOperatingOfficerMember 2022-09-02 2022-09-02 0001058307 nxpl:PredecessorCompanyMember 2022-08-30 0001058307 nxpl:NextPlatCorpMember nxpl:PredecessorCompanyMember 2022-08-30 0001058307 srt:ChiefExecutiveOfficerMember nxpl:PredecessorCompanyMember 2022-08-30 0001058307 nxpl:BoardMemberMember nxpl:PredecessorCompanyMember 2022-08-30 0001058307 nxpl:ReverseStockSplitMember 2022-12-30 2022-12-30 0001058307 nxpl:ProgressiveCareMember 2023-02-01 2023-02-01 0001058307 nxpl:ProgressiveCareMember 2023-05-01 2023-05-01 0001058307 nxpl:ProgressiveCareMember 2023-01-01 2023-09-30 0001058307 nxpl:ProgressiveCareMember 2024-01-01 2024-09-30 0001058307 nxpl:ProgressiveCareMember 2023-05-05 0001058307 nxpl:DebtConvertedToCommonStockMember nxpl:ProgressiveCareMember nxpl:NextPlatCorpMember 2023-05-09 2023-05-09 0001058307 nxpl:DebtConvertedToCommonStockMember nxpl:ProgressiveCareMember srt:ChiefExecutiveOfficerMember 2023-05-09 2023-05-09 0001058307 nxpl:DebtConvertedToCommonStockMember nxpl:ProgressiveCareMember nxpl:BoardMemberMember 2023-05-09 2023-05-09 0001058307 nxpl:InducementWarrantMember nxpl:ProgressiveCareMember srt:ChiefExecutiveOfficerMember 2023-05-09 0001058307 nxpl:InducementWarrantMember nxpl:ProgressiveCareMember nxpl:BoardMemberMember 2023-05-09 0001058307 nxpl:ProgressiveCareMember 2023-07-01 0001058307 nxpl:ProgressiveCareMember 2023-07-01 2023-07-01 0001058307 srt:ChiefExecutiveOfficerMember nxpl:ProgressiveCareMember 2023-07-01 0001058307 nxpl:BoardMemberMember nxpl:ProgressiveCareMember 2023-07-01 0001058307 nxpl:FernandezAndBarretoMember nxpl:ProgressiveCareMember 2023-07-01 0001058307 us-gaap:RelatedPartyMember 2023-07-07 2023-07-07 0001058307 us-gaap:RelatedPartyMember 2024-09-30 0001058307 us-gaap:RelatedPartyMember 2023-12-31 0001058307 nxpl:LaurenSturgesFernandezMember 2022-07-12 2022-07-12 0001058307 nxpl:LaurenSturgesFernandezMember 2022-01-01 2022-12-31 0001058307 nxpl:LaurenSturgesFernandezMember 2023-04-01 2023-04-30 0001058307 nxpl:TerminationOfEmploymentThomasSeifertCFOMember us-gaap:SubsequentEventMember 2024-10-15 2024-10-15 0001058307 nxpl:ProgressiveCareMember nxpl:FinanceObligationForPharmacyEquipmentMember 2018-05-31 0001058307 nxpl:ProgressiveCareMember nxpl:FinanceObligationForPharmacyEquipmentMember 2018-05-31 2018-05-31 utr:M 0001058307 2023-01-01 2023-12-31 0001058307 nxpl:OfficeSpaceInFloridaMember 2021-12-02 utr:sqft 0001058307 nxpl:OfficeSpaceInFloridaMember 2021-12-02 2021-12-02 0001058307 nxpl:FacilitiesInPooleEnglandMember 2024-09-30 0001058307 nxpl:FacilitiesInPooleEnglandMember 2024-07-01 2024-09-30 0001058307 nxpl:FacilitiesInPooleEnglandMember 2024-08-01 0001058307 nxpl:ProgressiveCareMember nxpl:OrlandoPharmacyMember 2020-08-31 0001058307 nxpl:ProgressiveCareMember nxpl:OrlandoPharmacyMember 2020-08-01 2020-08-31 0001058307 nxpl:ProgressiveCareMember nxpl:NorthMiamiBeachPharmacyMember 2021-09-30 0001058307 nxpl:ProgressiveCareMember nxpl:NorthMiamiBeachPharmacyMember 2021-09-01 2021-09-30 0001058307 nxpl:AircraftLeaseMember 2023-06-30 0001058307 nxpl:AircraftLeaseMember 2023-06-01 2023-06-30 0001058307 nxpl:AircraftLeaseMember 2024-06-01 2024-06-30 0001058307 us-gaap:SellingGeneralAndAdministrativeExpensesMember nxpl:AircraftLeaseMember 2024-06-01 2024-06-30 0001058307 us-gaap:OperatingSegmentsMember nxpl:PharmacyPrescriptionAndOtherRevenueNetOfPbmFeesMember nxpl:EcommerceMember 2024-07-01 2024-09-30 0001058307 us-gaap:OperatingSegmentsMember nxpl:PharmacyPrescriptionAndOtherRevenueNetOfPbmFeesMember nxpl:HealthcareOperationsMember 2024-07-01 2024-09-30 0001058307 srt:ConsolidationEliminationsMember nxpl:PharmacyPrescriptionAndOtherRevenueNetOfPbmFeesMember 2024-07-01 2024-09-30 0001058307 nxpl:PharmacyPrescriptionAndOtherRevenueNetOfPbmFeesMember 2024-07-01 2024-09-30 0001058307 us-gaap:OperatingSegmentsMember nxpl:EcommerceRevenueMember nxpl:EcommerceMember 2024-07-01 2024-09-30 0001058307 us-gaap:OperatingSegmentsMember nxpl:EcommerceRevenueMember nxpl:HealthcareOperationsMember 2024-07-01 2024-09-30 0001058307 srt:ConsolidationEliminationsMember nxpl:EcommerceRevenueMember 2024-07-01 2024-09-30 0001058307 nxpl:EcommerceRevenueMember 2024-07-01 2024-09-30 0001058307 us-gaap:OperatingSegmentsMember nxpl:Pharmacy340bContractMember nxpl:EcommerceMember 2024-07-01 2024-09-30 0001058307 us-gaap:OperatingSegmentsMember nxpl:Pharmacy340bContractMember nxpl:HealthcareOperationsMember 2024-07-01 2024-09-30 0001058307 srt:ConsolidationEliminationsMember nxpl:Pharmacy340bContractMember 2024-07-01 2024-09-30 0001058307 nxpl:Pharmacy340bContractMember 2024-07-01 2024-09-30 0001058307 us-gaap:OperatingSegmentsMember nxpl:EcommerceMember 2024-07-01 2024-09-30 0001058307 us-gaap:OperatingSegmentsMember nxpl:HealthcareOperationsMember 2024-07-01 2024-09-30 0001058307 srt:ConsolidationEliminationsMember 2024-07-01 2024-09-30 0001058307 us-gaap:OperatingSegmentsMember nxpl:SegmentExpenseMember nxpl:EcommerceMember 2024-07-01 2024-09-30 0001058307 us-gaap:OperatingSegmentsMember nxpl:SegmentExpenseMember nxpl:HealthcareOperationsMember 2024-07-01 2024-09-30 0001058307 srt:ConsolidationEliminationsMember nxpl:SegmentExpenseMember 2024-07-01 2024-09-30 0001058307 nxpl:SegmentExpenseMember 2024-07-01 2024-09-30 0001058307 nxpl:ApproximationMember 2024-07-01 2024-09-30 0001058307 us-gaap:OperatingSegmentsMember nxpl:PharmacyPrescriptionAndOtherRevenueNetOfPbmFeesMember nxpl:EcommerceMember 2023-07-01 2023-09-30 0001058307 us-gaap:OperatingSegmentsMember nxpl:PharmacyPrescriptionAndOtherRevenueNetOfPbmFeesMember nxpl:HealthcareOperationsMember 2023-07-01 2023-09-30 0001058307 srt:ConsolidationEliminationsMember nxpl:PharmacyPrescriptionAndOtherRevenueNetOfPbmFeesMember 2023-07-01 2023-09-30 0001058307 nxpl:PharmacyPrescriptionAndOtherRevenueNetOfPbmFeesMember 2023-07-01 2023-09-30 0001058307 us-gaap:OperatingSegmentsMember nxpl:EcommerceRevenueMember nxpl:EcommerceMember 2023-07-01 2023-09-30 0001058307 us-gaap:OperatingSegmentsMember nxpl:EcommerceRevenueMember nxpl:HealthcareOperationsMember 2023-07-01 2023-09-30 0001058307 srt:ConsolidationEliminationsMember nxpl:EcommerceRevenueMember 2023-07-01 2023-09-30 0001058307 nxpl:EcommerceRevenueMember 2023-07-01 2023-09-30 0001058307 us-gaap:OperatingSegmentsMember nxpl:Pharmacy340bContractMember nxpl:EcommerceMember 2023-07-01 2023-09-30 0001058307 us-gaap:OperatingSegmentsMember nxpl:Pharmacy340bContractMember nxpl:HealthcareOperationsMember 2023-07-01 2023-09-30 0001058307 srt:ConsolidationEliminationsMember nxpl:Pharmacy340bContractMember 2023-07-01 2023-09-30 0001058307 nxpl:Pharmacy340bContractMember 2023-07-01 2023-09-30 0001058307 us-gaap:OperatingSegmentsMember nxpl:EcommerceMember 2023-07-01 2023-09-30 0001058307 us-gaap:OperatingSegmentsMember nxpl:HealthcareOperationsMember 2023-07-01 2023-09-30 0001058307 srt:ConsolidationEliminationsMember 2023-07-01 2023-09-30 0001058307 us-gaap:OperatingSegmentsMember nxpl:SegmentExpenseMember nxpl:EcommerceMember 2023-07-01 2023-09-30 0001058307 us-gaap:OperatingSegmentsMember nxpl:SegmentExpenseMember nxpl:HealthcareOperationsMember 2023-07-01 2023-09-30 0001058307 srt:ConsolidationEliminationsMember nxpl:SegmentExpenseMember 2023-07-01 2023-09-30 0001058307 nxpl:SegmentExpenseMember 2023-07-01 2023-09-30 0001058307 us-gaap:OperatingSegmentsMember nxpl:PharmacyPrescriptionAndOtherRevenueNetOfPbmFeesMember nxpl:EcommerceMember 2024-01-01 2024-09-30 0001058307 us-gaap:OperatingSegmentsMember nxpl:PharmacyPrescriptionAndOtherRevenueNetOfPbmFeesMember nxpl:HealthcareOperationsMember 2024-01-01 2024-09-30 0001058307 srt:ConsolidationEliminationsMember nxpl:PharmacyPrescriptionAndOtherRevenueNetOfPbmFeesMember 2024-01-01 2024-09-30 0001058307 nxpl:PharmacyPrescriptionAndOtherRevenueNetOfPbmFeesMember 2024-01-01 2024-09-30 0001058307 us-gaap:OperatingSegmentsMember nxpl:EcommerceRevenueMember nxpl:EcommerceMember 2024-01-01 2024-09-30 0001058307 us-gaap:OperatingSegmentsMember nxpl:EcommerceRevenueMember nxpl:HealthcareOperationsMember 2024-01-01 2024-09-30 0001058307 srt:ConsolidationEliminationsMember nxpl:EcommerceRevenueMember 2024-01-01 2024-09-30 0001058307 nxpl:EcommerceRevenueMember 2024-01-01 2024-09-30 0001058307 us-gaap:OperatingSegmentsMember nxpl:Pharmacy340bContractMember nxpl:EcommerceMember 2024-01-01 2024-09-30 0001058307 us-gaap:OperatingSegmentsMember nxpl:Pharmacy340bContractMember nxpl:HealthcareOperationsMember 2024-01-01 2024-09-30 0001058307 srt:ConsolidationEliminationsMember nxpl:Pharmacy340bContractMember 2024-01-01 2024-09-30 0001058307 nxpl:Pharmacy340bContractMember 2024-01-01 2024-09-30 0001058307 us-gaap:OperatingSegmentsMember nxpl:EcommerceMember 2024-01-01 2024-09-30 0001058307 us-gaap:OperatingSegmentsMember nxpl:HealthcareOperationsMember 2024-01-01 2024-09-30 0001058307 srt:ConsolidationEliminationsMember 2024-01-01 2024-09-30 0001058307 us-gaap:OperatingSegmentsMember nxpl:SegmentExpenseMember nxpl:EcommerceMember 2024-01-01 2024-09-30 0001058307 us-gaap:OperatingSegmentsMember nxpl:SegmentExpenseMember nxpl:HealthcareOperationsMember 2024-01-01 2024-09-30 0001058307 srt:ConsolidationEliminationsMember nxpl:SegmentExpenseMember 2024-01-01 2024-09-30 0001058307 nxpl:SegmentExpenseMember 2024-01-01 2024-09-30 0001058307 us-gaap:OperatingSegmentsMember nxpl:PharmacyPrescriptionAndOtherRevenueNetOfPbmFeesMember nxpl:EcommerceMember 2023-01-01 2023-09-30 0001058307 us-gaap:OperatingSegmentsMember nxpl:PharmacyPrescriptionAndOtherRevenueNetOfPbmFeesMember nxpl:HealthcareOperationsMember 2023-01-01 2023-09-30 0001058307 srt:ConsolidationEliminationsMember nxpl:PharmacyPrescriptionAndOtherRevenueNetOfPbmFeesMember 2023-01-01 2023-09-30 0001058307 nxpl:PharmacyPrescriptionAndOtherRevenueNetOfPbmFeesMember 2023-01-01 2023-09-30 0001058307 us-gaap:OperatingSegmentsMember nxpl:EcommerceRevenueMember nxpl:EcommerceMember 2023-01-01 2023-09-30 0001058307 us-gaap:OperatingSegmentsMember nxpl:EcommerceRevenueMember nxpl:HealthcareOperationsMember 2023-01-01 2023-09-30 0001058307 srt:ConsolidationEliminationsMember nxpl:EcommerceRevenueMember 2023-01-01 2023-09-30 0001058307 nxpl:EcommerceRevenueMember 2023-01-01 2023-09-30 0001058307 us-gaap:OperatingSegmentsMember nxpl:Pharmacy340bContractMember nxpl:EcommerceMember 2023-01-01 2023-09-30 0001058307 us-gaap:OperatingSegmentsMember nxpl:Pharmacy340bContractMember nxpl:HealthcareOperationsMember 2023-01-01 2023-09-30 0001058307 srt:ConsolidationEliminationsMember nxpl:Pharmacy340bContractMember 2023-01-01 2023-09-30 0001058307 nxpl:Pharmacy340bContractMember 2023-01-01 2023-09-30 0001058307 us-gaap:OperatingSegmentsMember nxpl:EcommerceMember 2023-01-01 2023-09-30 0001058307 us-gaap:OperatingSegmentsMember nxpl:HealthcareOperationsMember 2023-01-01 2023-09-30 0001058307 srt:ConsolidationEliminationsMember 2023-01-01 2023-09-30 0001058307 us-gaap:OperatingSegmentsMember nxpl:SegmentExpenseMember nxpl:EcommerceMember 2023-01-01 2023-09-30 0001058307 us-gaap:OperatingSegmentsMember nxpl:SegmentExpenseMember nxpl:HealthcareOperationsMember 2023-01-01 2023-09-30 0001058307 srt:ConsolidationEliminationsMember nxpl:SegmentExpenseMember 2023-01-01 2023-09-30 0001058307 nxpl:SegmentExpenseMember 2023-01-01 2023-09-30 0001058307 us-gaap:OperatingSegmentsMember nxpl:EcommerceMember 2024-09-30 0001058307 us-gaap:OperatingSegmentsMember nxpl:HealthcareOperationsMember 2024-09-30 0001058307 srt:ConsolidationEliminationsMember 2024-09-30 0001058307 us-gaap:OperatingSegmentsMember nxpl:EcommerceMember 2023-12-31 0001058307 us-gaap:OperatingSegmentsMember nxpl:HealthcareOperationsMember 2023-12-31 0001058307 srt:ConsolidationEliminationsMember 2023-12-31 0001058307 us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember nxpl:AmazonMember 2024-01-01 2024-09-30 0001058307 us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember nxpl:AmazonMember 2023-01-01 2023-09-30 0001058307 nxpl:PurchasesMember us-gaap:SupplierConcentrationRiskMember nxpl:IridiumSatelliteMember 2024-07-01 2024-09-30 0001058307 nxpl:PurchasesMember us-gaap:SupplierConcentrationRiskMember nxpl:IridiumSatelliteMember 2023-07-01 2023-09-30 0001058307 nxpl:PurchasesMember us-gaap:SupplierConcentrationRiskMember nxpl:GarminMember 2024-07-01 2024-09-30 0001058307 nxpl:PurchasesMember us-gaap:SupplierConcentrationRiskMember nxpl:GarminMember 2023-07-01 2023-09-30 0001058307 nxpl:PurchasesMember us-gaap:SupplierConcentrationRiskMember nxpl:GlobalstarEuropeMember 2024-07-01 2024-09-30 0001058307 nxpl:PurchasesMember us-gaap:SupplierConcentrationRiskMember nxpl:GlobalstarEuropeMember 2023-07-01 2023-09-30 0001058307 nxpl:PurchasesMember us-gaap:SupplierConcentrationRiskMember nxpl:MaklinkMember 2024-07-01 2024-09-30 0001058307 nxpl:PurchasesMember us-gaap:SupplierConcentrationRiskMember nxpl:MaklinkMember 2023-07-01 2023-09-30 0001058307 nxpl:PurchasesMember us-gaap:SupplierConcentrationRiskMember nxpl:GarminMember 2024-01-01 2024-09-30 0001058307 nxpl:PurchasesMember us-gaap:SupplierConcentrationRiskMember nxpl:GarminMember 2023-01-01 2023-09-30 0001058307 nxpl:PurchasesMember us-gaap:SupplierConcentrationRiskMember nxpl:IridiumSatelliteMember 2024-01-01 2024-09-30 0001058307 nxpl:PurchasesMember us-gaap:SupplierConcentrationRiskMember nxpl:IridiumSatelliteMember 2023-01-01 2023-09-30 0001058307 nxpl:PurchasesMember us-gaap:SupplierConcentrationRiskMember nxpl:GlobalstarEuropeMember 2024-01-01 2024-09-30 0001058307 nxpl:PurchasesMember us-gaap:SupplierConcentrationRiskMember nxpl:GlobalstarEuropeMember 2023-01-01 2023-09-30 0001058307 us-gaap:SalesRevenueNetMember us-gaap:GeographicConcentrationRiskMember srt:EuropeMember 2024-07-01 2024-09-30 0001058307 us-gaap:SalesRevenueNetMember us-gaap:GeographicConcentrationRiskMember srt:EuropeMember 2023-07-01 2023-09-30 0001058307 us-gaap:SalesRevenueNetMember us-gaap:GeographicConcentrationRiskMember srt:NorthAmericaMember 2024-07-01 2024-09-30 0001058307 us-gaap:SalesRevenueNetMember us-gaap:GeographicConcentrationRiskMember srt:NorthAmericaMember 2023-07-01 2023-09-30 0001058307 us-gaap:SalesRevenueNetMember us-gaap:GeographicConcentrationRiskMember srt:SouthAmericaMember 2024-07-01 2024-09-30 0001058307 us-gaap:SalesRevenueNetMember us-gaap:GeographicConcentrationRiskMember srt:SouthAmericaMember 2023-07-01 2023-09-30 0001058307 us-gaap:SalesRevenueNetMember us-gaap:GeographicConcentrationRiskMember srt:AsiaPacificMember 2024-07-01 2024-09-30 0001058307 us-gaap:SalesRevenueNetMember us-gaap:GeographicConcentrationRiskMember srt:AsiaPacificMember 2023-07-01 2023-09-30 0001058307 us-gaap:SalesRevenueNetMember us-gaap:GeographicConcentrationRiskMember srt:AfricaMember 2024-07-01 2024-09-30 0001058307 us-gaap:SalesRevenueNetMember us-gaap:GeographicConcentrationRiskMember srt:AfricaMember 2023-07-01 2023-09-30 0001058307 us-gaap:SalesRevenueNetMember us-gaap:GeographicConcentrationRiskMember nxpl:AllCountriesMember 2024-07-01 2024-09-30 0001058307 us-gaap:SalesRevenueNetMember us-gaap:GeographicConcentrationRiskMember nxpl:AllCountriesMember 2023-07-01 2023-09-30 0001058307 us-gaap:SalesRevenueNetMember us-gaap:GeographicConcentrationRiskMember srt:EuropeMember 2024-01-01 2024-09-30 0001058307 us-gaap:SalesRevenueNetMember us-gaap:GeographicConcentrationRiskMember srt:EuropeMember 2023-01-01 2023-09-30 0001058307 us-gaap:SalesRevenueNetMember us-gaap:GeographicConcentrationRiskMember srt:NorthAmericaMember 2024-01-01 2024-09-30 0001058307 us-gaap:SalesRevenueNetMember us-gaap:GeographicConcentrationRiskMember srt:NorthAmericaMember 2023-01-01 2023-09-30 0001058307 us-gaap:SalesRevenueNetMember us-gaap:GeographicConcentrationRiskMember srt:SouthAmericaMember 2024-01-01 2024-09-30 0001058307 us-gaap:SalesRevenueNetMember us-gaap:GeographicConcentrationRiskMember srt:SouthAmericaMember 2023-01-01 2023-09-30 0001058307 us-gaap:SalesRevenueNetMember us-gaap:GeographicConcentrationRiskMember srt:AsiaPacificMember 2024-01-01 2024-09-30 0001058307 us-gaap:SalesRevenueNetMember us-gaap:GeographicConcentrationRiskMember srt:AsiaPacificMember 2023-01-01 2023-09-30 0001058307 us-gaap:SalesRevenueNetMember us-gaap:GeographicConcentrationRiskMember srt:AfricaMember 2024-01-01 2024-09-30 0001058307 us-gaap:SalesRevenueNetMember us-gaap:GeographicConcentrationRiskMember srt:AfricaMember 2023-01-01 2023-09-30 0001058307 us-gaap:SalesRevenueNetMember us-gaap:GeographicConcentrationRiskMember nxpl:AllCountriesMember 2024-01-01 2024-09-30 0001058307 us-gaap:SalesRevenueNetMember us-gaap:GeographicConcentrationRiskMember nxpl:AllCountriesMember 2023-01-01 2023-09-30 0001058307 nxpl:PurchasesMember us-gaap:SupplierConcentrationRiskMember 2024-01-01 2024-09-30 0001058307 nxpl:PurchasesMember us-gaap:SupplierConcentrationRiskMember nxpl:OneVendorMember 2024-01-01 2024-09-30 0001058307 nxpl:ReimbursementsMember us-gaap:CustomerConcentrationRiskMember nxpl:PbmAMember 2024-01-01 2024-09-30 0001058307 nxpl:ReimbursementsMember us-gaap:CustomerConcentrationRiskMember nxpl:PbmBMember 2024-01-01 2024-09-30 0001058307 nxpl:ReimbursementsMember us-gaap:CustomerConcentrationRiskMember nxpl:PbmCMember 2024-01-01 2024-09-30 0001058307 us-gaap:AccountsReceivableMember 2024-01-01 2024-09-30

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 10-Q

☒ | QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended September 30, 2024

OR

☐ | TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE EXCHANGE ACT

For the transition period from ______________to _______________.

Commission File Number 001-40447

NEXTPLAT CORP

(Exact name of registrant as specified in its charter)

Nevada |  | 65-0783722
(State or other jurisdiction of incorporation or organization) |  | (I.R.S. Employer Identification No.)
3250 Mary St., Suite 410, Coconut Grove, FL |  | 33133
(Address of principal executive offices) |  | (Zip Code)

(305)-560-5355

Registrant’s telephone number, including area code

Securities registered pursuant to Section 12(b) of the Act:

Title of each class |  | Trading Symbol(s) |  | Name of each exchange on which registered
Common Stock, par value $0.0001 |  | NXPL |  | The Nasdaq Stock Market Inc.
Warrants |  | NXPLW |  | The Nasdaq Stock Market Inc.

Indicate by check whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☒ No ☐

Indicate by check whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes ☒ No ☐

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

Large accelerated filer ☐ | Accelerated filer ☐
Non-accelerated filer ☒ | Smaller reporting company ☒
| Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Indicate by check mark whether the registrant is a shell company (as defined by Rule 12b-2 of the Exchange Act). Yes ☐ No ☒

Indicate the number of shares outstanding of each of the registrant’s classes of common stock as of the latest practicable date.

Class |  | Outstanding at November 8, 2024
Common Stock, $0.0001 par value |  | 25,963,051

Table of Contents

FORM 10-Q

INDEX

| Page
PART I. FINANCIAL INFORMATION
ITEM 1. CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED) | 2
CONDENSED CONSOLIDATED BALANCE SHEETS | 2
CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE (LOSS) INCOME | 3
CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN EQUITY | 4
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS | 5
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS | 6
ITEM 2. MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS | 32
ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK | 46
ITEM 4. CONTROLS AND PROCEDURES | 46
PART II. OTHER INFORMATION
ITEM 1. LEGAL PROCEEDINGS | 47
ITEM 1A. RISK FACTORS | 47
ITEM 2. UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS | 47
ITEM 3. DEFAULTS UPON SENIOR SECURITIES | 47
ITEM 4. MINE SAFETY DISCLOSURES | 47
ITEM 5. OTHER INFORMATION | 47
ITEM 6. EXHIBITS | 48
SIGNATURES | 49

i

Table of Contents

SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS

This quarterly report and other documents that we file with the Securities and Exchange Commission (“SEC”) contain forward-looking statements that are based on current expectations, estimates, forecasts and projections about our future performance, our business, our beliefs and our management’s assumptions. Statements that are not historical facts are forward-looking statements, including forward-looking information concerning sales trends, gross margins, number and location of new store openings, outcomes of litigation, the level of capital expenditures, industry trends, demographic trends, growth strategies, financial results, cost reduction initiatives, acquisition synergies, regulatory approvals, and competitive strengths. Words such as “expect,” “outlook,” “forecast,” “would,” “could,” “should,” “project,” “intend,” “plan,” “continue,” “sustain,” “on track,” “believe,” “seek,” “estimate,” “anticipate,” “may,” “assume,” and variations of such words and similar expressions are often used to identify such forward-looking statements, which are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are not guarantees of future performance and involve risks, assumptions and uncertainties, including, but not limited to, those described in our Annual Report on Form 10-K for the year ended December 31, 2023 filed with the SEC on April 11, 2024 (“2023 Form 10-K”), this quarterly report on Form 10-Q for the three and nine months ended September 30, 2024, and our other reports that we file or furnish with the SEC. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those indicated or anticipated by such forward-looking statements. Accordingly, you are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date they are made. Except to the extent required by law, we undertake no obligation to update publicly any forward-looking statements after the date they are made, whether as a result of new information, future events, changes in assumptions or otherwise.

ii

Table of Contents

PART I. FINANCIAL INFORMATION

ITEM 1. CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED)

The accompanying Unaudited Condensed Consolidated Financial Statements of NextPlat Corp, (“NextPlat,” the “Company,” “we,” or “our”), for the three and nine months ended September 30, 2024 and for comparable periods in the prior year are included below. The financial statements should be read in conjunction with the notes to financial statements that follow.

NEXTPLAT CORP AND SUBSIDIARIES

CONDENSED CONSOLIDATED BALANCE SHEETS

(In thousands, except shares and par data)

(Unaudited)

|  | September 30, 2024 |  |  | December 31, 2023 |
ASSETS |  |  |  |  |  |  |  |
Current Assets |  |  |  |  |  |  |  |
Cash |  | $ | 20,360 |  |  | $ | 26,307 |
Accounts receivable, net |  |  | 6,575 |  |  |  | 8,923 |
Receivables - other, net |  |  | 1,235 |  |  |  | 1,846 |
Inventories, net |  |  | 6,362 |  |  |  | 5,135 |
Unbilled revenue |  |  | 219 |  |  |  | 189 |
VAT receivable |  |  | 350 |  |  |  | 342 |
Prepaid expenses |  |  | 484 |  |  |  | 640 |
Notes receivable due from related party, net of allowances of $63 and $0 at September 30, 2024 and December 31, 2023, respectively |  |  | 206 |  |  |  | 256 |
Total Current Assets |  |  | 35,791 |  |  |  | 43,638 |
Property and equipment, net |  |  | 3,595 |  |  |  | 3,989 |
Goodwill |  |  | 156 |  |  |  | 731 |
Intangible assets, net |  |  | 555 |  |  |  | 14,423 |
Operating right of use assets, net |  |  | 898 |  |  |  | 1,566 |
Finance right-of-use assets, net |  |  | 10 |  |  |  | 22 |
Deposits |  |  | 94 |  |  |  | 39 |
Prepaid expenses, net of current portion |  |  | — |  |  |  | 61 |
Total Other Assets |  |  | 1,713 |  |  |  | 16,842 |
Total Assets |  | $ | 41,099 |  |  | $ | 64,469 |
LIABILITIES AND EQUITY |  |  |  |  |  |  |  |
Current Liabilities |  |  |  |  |  |  |  |
Accounts payable and accrued expenses |  | $ | 8,531 |  |  | $ | 13,176 |
Contract liabilities |  |  | 104 |  |  |  | 42 |
Notes payable |  |  | 461 |  |  |  | 312 |
Due to related party |  |  | 24 |  |  |  | 18 |
Operating lease liabilities |  |  | 381 |  |  |  | 532 |
Finance lease liabilities |  |  | 10 |  |  |  | 18 |
Income taxes payable |  |  | 162 |  |  |  | 139 |
Total Current Liabilities |  |  | 9,673 |  |  |  | 14,237 |
Long Term Liabilities: |  |  |  |  |  |  |  |
Notes payable, net of current portion |  |  | 1,080 |  |  |  | 1,211 |
Operating lease liabilities, net of current portion |  |  | 553 |  |  |  | 929 |
Finance lease liabilities, net of current portion |  |  | — |  |  |  | 5 |
Total Liabilities |  |  | 11,306 |  |  |  | 16,382 |
Commitments and Contingencies |  |  | — |  |  |  | — |
Equity |  |  |  |  |  |  |  |
Preferred stock ($0.0001 par value; 3,333,333 shares authorized) |  |  | — |  |  |  | — |
Common stock ($0.0001 par value; 50,000,000 shares authorized, 18,993,146 and 18,724,596 shares issued and outstanding as of September 30, 2024 and December 31, 2023, respectively) |  |  | 2 |  |  |  | 2 |
Additional paid-in capital |  |  | 68,487 |  |  |  | 67,170 |
Accumulated deficit |  |  | (45,933 | ) |  |  | (34,925 | )
Accumulated other comprehensive loss |  |  | (93 | ) |  |  | (63 | )
Equity attributable to NextPlat Corp stockholders |  |  | 22,463 |  |  |  | 32,184 |
Equity attributable to non-controlling interests |  |  | 7,330 |  |  |  | 15,903 |
Total Equity |  |  | 29,793 |  |  |  | 48,087 |
Total Liabilities and Equity |  | $ | 41,099 |  |  | $ | 64,469 |

See accompanying notes to unaudited condensed consolidated financial statements.

2

Table of Contents

NEXTPLAT CORP AND SUBSIDIARIES

CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE (LOSS) INCOME

(In thousands, except per share data)

(Unaudited)

|  | Three Months Ended September 30, |  |  | Nine Months Ended September 30, |
|  | 2024 |  |  | 2023 |  |  | 2024 |  |  | 2023 |
Sales of products, net |  | $ | 12,865 |  |  | $ | 12,789 |  |  | $ | 41,015 |  |  | $ | 18,622 |
Revenues from services |  |  | 2,502 |  |  |  | 2,501 |  |  |  | 8,834 |  |  |  | 2,501 |
Revenue, net |  |  | 15,367 |  |  |  | 15,290 |  |  |  | 49,849 |  |  |  | 21,123 |
Cost of products |  |  | 11,799 |  |  |  | 10,634 |  |  |  | 35,539 |  |  |  | 15,003 |
Cost of services |  |  | 48 |  |  |  | 71 |  |  |  | 174 |  |  |  | 71 |
Cost of revenue |  |  | 11,847 |  |  |  | 10,705 |  |  |  | 35,713 |  |  |  | 15,074 |
Gross profit |  |  | 3,520 |  |  |  | 4,585 |  |  |  | 14,136 |  |  |  | 6,049 |
Operating expenses: |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Selling, general and administrative |  |  | 2,293 |  |  |  | 4,187 |  |  |  | 6,516 |  |  |  | 7,496 |
Salaries, wages and payroll taxes |  |  | 2,875 |  |  |  | 2,483 |  |  |  | 8,284 |  |  |  | 4,039 |
Impairment loss |  |  | 3,729 |  |  |  | — |  |  |  | 13,653 |  |  |  | — |
Professional fees |  |  | 2,144 |  |  |  | 521 |  |  |  | 4,133 |  |  |  | 1,385 |
Depreciation and amortization |  |  | 478 |  |  |  | 871 |  |  |  | 2,287 |  |  |  | 1,201 |
Total operating expenses |  |  | 11,519 |  |  |  | 8,062 |  |  |  | 34,873 |  |  |  | 14,121 |
Loss before other (income) expense |  |  | (7,999 | ) |  |  | (3,477 | ) |  |  | (20,737 | ) |  |  | (8,072 | )
Other (income) expense: |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Gain on sale or disposal of property and equipment |  |  | (98 | ) |  |  | — |  |  |  | (98 | ) |  |  | — |
Interest expense |  |  | 22 |  |  |  | 46 |  |  |  | 62 |  |  |  | 56 |
Interest earned |  |  | (183 | ) |  |  | (210 | ) |  |  | (596 | ) |  |  | (393 | )
Other income |  |  | (2 | ) |  |  | — |  |  |  | (2 | ) |  |  | (316 | )
Foreign currency exchange rate variance |  |  | (119 | ) |  |  | 165 |  |  |  | (87 | ) |  |  | 95 |
Total other (income) expense |  |  | (380 | ) |  |  | 1 |  |  |  | (721 | ) |  |  | (558 | )
Loss before income taxes and equity in net loss of affiliate |  |  | (7,619 | ) |  |  | (3,478 | ) |  |  | (20,016 | ) |  |  | (7,514 | )
Income taxes |  |  | (45 | ) |  |  | (23 | ) |  |  | (92 | ) |  |  | (75 | )
Loss before equity in net loss of affiliate |  |  | (7,664 | ) |  |  | (3,501 | ) |  |  | (20,108 | ) |  |  | (7,589 | )
Gain on remeasurement of fair value of equity interest in affiliate prior to acquisition |  |  | — |  |  |  | 6,138 |  |  |  | — |  |  |  | 6,138 |
Equity in net loss of affiliate |  |  | — |  |  |  | — |  |  |  | — |  |  |  | (1,440 | )
Net (loss) income |  |  | (7,664 | ) |  |  | 2,637 |  |  |  | (20,108 | ) |  |  | (2,891 | )
Net loss attributable to non-controlling interest |  |  | 3,448 |  |  |  | 811 |  |  |  | 9,100 |  |  |  | 811 |
Net (loss) income attributable to NextPlat Corp |  | $ | (4,216 | ) |  | $ | 3,448 |  |  | $ | (11,008 | ) |  | $ | (2,080 | )
Comprehensive (loss) income: |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Net (loss) income |  | $ | (7,664 | ) |  | $ | 2,637 |  |  | $ | (20,108 | ) |  | $ | (2,891 | )
Foreign currency (loss) gain |  |  | 6 |  |  |  | 19 |  |  |  | (30 | ) |  |  | (16 | )
Comprehensive (loss) income |  | $ | (7,658 | ) |  | $ | 2,656 |  |  | $ | (20,138 | ) |  | $ | (2,907 | )
NET (LOSS) INCOME ATTRIBUTABLE TO COMMON STOCKHOLDERS |  | $ | (4,216 | ) |  | $ | 3,448 |  |  | $ | (11,008 | ) |  | $ | (2,080 | )
Weighted number of common shares outstanding – basic |  |  | 18,982 |  |  |  | 18,703 |  |  |  | 18,844 |  |  |  | 17,079 |
Weighted number of common shares outstanding – diluted |  |  | 18,982 |  |  |  | 20,310 |  |  |  | 18,844 |  |  |  | 17,079 |
Basic (loss) earnings per share |  | $ | (0.22 | ) |  | $ | 0.18 |  |  | $ | (0.58 | ) |  | $ | (0.12 | )
Diluted (loss) earnings per share |  | $ | (0.22 | ) |  | $ | 0.17 |  |  | $ | (0.58 | ) |  | $ | (0.12 | )

See accompanying notes to unaudited condensed consolidated financial statements.

3

Table of Contents

NEXTPLAT CORP AND SUBSIDIARIES

CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN EQUITY

(In thousands)

(Unaudited)

For the Three and Nine Months Ended September 30, 2024

|  | Common Stock |  |  | Additional |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
|  | $0.0001 Par Value |  |  | Paid in |  |  | Accumulated |  |  | Comprehensive |  |  | Stockholders’ |  |  | Non-controlling |  |  | Total |
|  | Shares |  |  | Amount |  |  | Capital |  |  | Deficit |  |  | Loss |  |  | Equity |  |  | Interests |  |  | Equity |
Balance at December 31, 2023 |  |  | 18,725 |  |  | $ | 2 |  |  | $ | 67,170 |  |  | $ | (34,925 | ) |  | $ | (63 | ) |  | $ | 32,184 |  |  | $ | 15,903 |  |  | $ | 48,087 |
Stock-based compensation in connection with options granted |  |  | — |  |  |  | — |  |  |  | 160 |  |  |  | — |  |  |  | — |  |  |  | 160 |  |  |  | — |  |  |  | 160 |
Stock-based compensation in connection with restricted stock awards |  |  | — |  |  |  | — |  |  |  | 387 |  |  |  | — |  |  |  | — |  |  |  | 387 |  |  |  | 65 |  |  |  | 452 |
Capital contribution of non-controlling interests |  |  | — |  |  |  | — |  |  |  | — |  |  |  | — |  |  |  | — |  |  |  | — |  |  |  | 122 |  |  |  | 122 |
Comprehensive loss |  |  | — |  |  |  | — |  |  |  | — |  |  |  | — |  |  |  | (27 | ) |  |  | (27 | ) |  |  | — |  |  |  | (27 | )
Net loss |  |  | — |  |  |  | — |  |  |  | — |  |  |  | (1,481 | ) |  |  | — |  |  |  | (1,481 | ) |  |  | (220 | ) |  |  | (1,701 | )
Balance at March 31, 2024 |  |  | 18,725 |  |  |  | 2 |  |  |  | 67,717 |  |  |  | (36,406 | ) |  |  | (90 | ) |  |  | 31,223 |  |  |  | 15,870 |  |  |  | 47,093 |
Stock-based compensation in connection with options granted |  |  | — |  |  |  | — |  |  |  | 159 |  |  |  | — |  |  |  | — |  |  |  | 159 |  |  |  | — |  |  |  | 159 |
Issuance of common stock related to restricted stock award |  |  | 200 |  |  |  | — |  |  |  | 387 |  |  |  | — |  |  |  | — |  |  |  | 387 |  |  |  | — |  |  |  | 387 |
Issuance of common stock related to exercise of warrants |  |  | 48 |  |  |  | — |  |  |  | 85 |  |  |  | — |  |  |  | — |  |  |  | 85 |  |  |  | — |  |  |  | 85 |
Comprehensive loss |  |  | — |  |  |  | — |  |  |  | — |  |  |  | — |  |  |  | (9 | ) |  |  | (9 | ) |  |  | — |  |  |  | (9 | )
Net loss |  |  | — |  |  |  | — |  |  |  | — |  |  |  | (5,311 | ) |  |  | — |  |  |  | (5,311 | ) |  |  | (5,432 | ) |  |  | (10,743 | )
Balance at June 30, 2024 |  |  | 18,973 |  |  |  | 2 |  |  |  | 68,348 |  |  |  | (41,717 | ) |  |  | (99 | ) |  |  | 26,534 |  |  |  | 10,438 |  |  |  | 36,972 |
Stock-based compensation in connection with options granted |  |  | — |  |  |  | — |  |  |  | 115 |  |  |  | — |  |  |  | — |  |  |  | 115 |  |  |  | — |  |  |  | 115 |
Issuance of common stock related to restricted stock award |  |  | 20 |  |  |  | — |  |  |  | 24 |  |  |  | — |  |  |  | — |  |  |  | 24 |  |  |  | 340 |  |  |  | 364 |
Comprehensive loss |  |  | — |  |  |  | — |  |  |  | — |  |  |  | — |  |  |  | 6 |  |  |  | 6 |  |  |  | — |  |  |  | 6 |
Net loss |  |  | — |  |  |  | — |  |  |  | — |  |  |  | (4,216 | ) |  |  | — |  |  |  | (4,216 | ) |  |  | (3,448 | ) |  |  | (7,664 | )
Balance at September 30, 2024 |  |  | 18,993 |  |  | $ | 2 |  |  | $ | 68,487 |  |  | $ | (45,933 | ) |  | $ | (93 | ) |  | $ | 22,463 |  |  | $ | 7,330 |  |  | $ | 29,793 |

For the Three and Nine Months Ended September 30, 2023

|  | Common Stock |  |  | Additional |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
|  | $0.0001 Par Value |  |  | Paid in |  |  | Accumulated |  |  | Comprehensive |  |  | Stockholders’ |  |  | Non-controlling |  |  | Total |
|  | Shares |  |  | Amount |  |  | Capital |  |  | Deficit |  |  | Loss |  |  | Equity |  |  | Interests |  |  | Equity |
Balance at December 31, 2022 |  |  | 14,402 |  |  | $ | 1 |  |  | $ | 56,963 |  |  | $ | (31,147 | ) |  | $ | (41 | ) |  | $ | 25,776 |  |  | $ | — |  |  | $ | 25,776 |
Issuance of common stock related to restricted stock award |  |  | 39 |  |  |  | — |  |  |  | 61 |  |  |  | — |  |  |  | — |  |  |  | 61 |  |  |  | — |  |  |  | 61 |
Comprehensive loss |  |  | — |  |  |  | — |  |  |  | — |  |  |  | — |  |  |  | (23 | ) |  |  | (23 | ) |  |  | — |  |  |  | (23 | )
Net loss |  |  | — |  |  |  | — |  |  |  | — |  |  |  | (1,187 | ) |  |  | — |  |  |  | (1,187 | ) |  |  | — |  |  |  | (1,187 | )
Balance at March 31, 2023 |  |  | 14,441 |  |  |  | 1 |  |  |  | 57,024 |  |  |  | (32,334 | ) |  |  | (64 | ) |  |  | 24,627 |  |  |  | — |  |  |  | 24,627 |
Issuance of common stock related to April offering |  |  | 3,429 |  |  |  | 1 |  |  |  | 5,999 |  |  |  | — |  |  |  | — |  |  |  | 6,000 |  |  |  | — |  |  |  | 6,000 |
Issuance of common stock related to exercise of warrants |  |  | 105 |  |  |  | — |  |  |  | 184 |  |  |  | — |  |  |  | — |  |  |  | 184 |  |  |  | — |  |  |  | 184 |
Issuance of common stock related to restricted stock award |  |  | 725 |  |  |  | — |  |  |  | 1,183 |  |  |  | — |  |  |  | — |  |  |  | 1,183 |  |  |  | — |  |  |  | 1,183 |
Stock-based compensation in connection with options granted |  |  | — |  |  |  | — |  |  |  | 781 |  |  |  | — |  |  |  | — |  |  |  | 781 |  |  |  | — |  |  |  | 781 |
Comprehensive loss |  |  | — |  |  |  | — |  |  |  | — |  |  |  | — |  |  |  | (12 | ) |  |  | (12 | ) |  |  | — |  |  |  | (12 | )
Net loss |  |  | — |  |  |  | — |  |  |  | — |  |  |  | (4,341 | ) |  |  | — |  |  |  | (4,341 | ) |  |  | — |  |  |  | (4,341 | )
Balance at June 30, 2023 |  |  | 18,700 |  |  |  | 2 |  |  |  | 65,171 |  |  |  | (36,675 | ) |  |  | (76 | ) |  |  | 28,422 |  |  |  | — |  |  |  | 28,422 |
Acquisition of subsidiary and noncontrolling interests |  |  | — |  |  |  | — |  |  |  | (35 | ) |  |  | — |  |  |  | — |  |  |  | (35 | ) |  |  | 15,957 |  |  |  | 15,922 |
Issuance of common stock related to restricted stock award |  |  | 25 |  |  |  | — |  |  |  | 837 |  |  |  | — |  |  |  | — |  |  |  | 837 |  |  |  | 150 |  |  |  | 987 |
Stock-based compensation in connection with options granted |  |  | — |  |  |  | — |  |  |  | 497 |  |  |  | — |  |  |  | — |  |  |  | 497 |  |  |  | 1,052 |  |  |  | 1,549 |
Comprehensive income |  |  | — |  |  |  | — |  |  |  | — |  |  |  | — |  |  |  | 19 |  |  |  | 19 |  |  |  | — |  |  |  | 19 |
Net income (loss) |  |  | — |  |  |  | — |  |  |  | — |  |  |  | 3,448 |  |  |  | — |  |  |  | 3,448 |  |  |  | (811 | ) |  |  | 2,637 |
Balance at September 30, 2023 |  |  | 18,725 |  |  | $ | 2 |  |  | $ | 66,470 |  |  | $ | (33,227 | ) |  | $ | (57 | ) |  | $ | 33,188 |  |  | $ | 16,348 |  |  | $ | 49,536 |

See accompanying notes to unaudited condensed consolidated financial statements.

4

Table of Contents

NEXTPLAT CORP AND SUBSIDIARIES

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

(In thousands)

(Unaudited)

|  | Nine Months Ended September 30, |
|  | 2024 |  |  | 2023 |
CASH FLOWS FROM OPERATING ACTIVITIES: |  |  |  |  |  |  |  |
Cash received from e-Commerce Operations revenue |  | $ | 9,862 |  |  | $ | 8,308 |
Cash received from Healthcare Operations revenue |  |  | 43,162 |  |  |  | 9,138 |
Cash received from interest income |  |  | 646 |  |  |  | 394 |
Cash received from other sources |  |  | 367 |  |  |  | 280 |
Cash paid for inventory purchases and other costs of revenue |  |  | (36,803 | ) |  |  | (12,963 | )
Cash paid for salaries and related expenses |  |  | (8,284 | ) |  |  | (4,039 | )
Cash paid for other recurring operating expenses |  |  | (10,410 | ) |  |  | (5,309 | )
Cash paid for interest expense |  |  | (41 | ) |  |  | (56 | )
Cash paid for income taxes |  |  | (69 | ) |  |  | — |
Cash paid for merger costs and other non-recurring expenses |  |  | (3,418 | ) |  |  | — |
Net cash used in operating activities |  |  | (4,988 | ) |  |  | (4,247 | )
CASH FLOWS FROM INVESTING ACTIVITIES: |  |  |  |  |  |  |  |
Purchase of property and equipment |  |  | (221 | ) |  |  | (458 | )
Capital contributions to equity method investee |  |  | — |  |  |  | (1,506 | )
Proceeds from sale or disposal of property and equipment |  |  | 98 |  |  |  | — |
Cash acquired in acquisition of Progressive Care subsidiary |  |  | — |  |  |  | 7,352 |
Cash acquired in acquisition of Outfitter Satellite subsidiary |  |  | 236 |  |  |  | — |
Cash paid in acquisition of Outfitter Satellite subsidiary |  |  | (1,094 | ) |  |  | — |
Net cash (used in) provided by investing activities |  |  | (981 | ) |  |  | 5,388 |
CASH FLOWS FROM FINANCING ACTIVITIES: |  |  |  |  |  |  |  |
Repayments of note payable, related party, net |  |  | — |  |  |  | (3 | )
Issuance of common stock for PIPE transaction |  |  | — |  |  |  | 6,000 |
Proceeds from exercise of warrants |  |  | 85 |  |  |  | 690 |
Capital contribution of non-controlling interest |  |  | 122 |  |  |  | — |
Payments on finance lease liabilities |  |  | (18 | ) |  |  | (9 | )
Repayments of notes payable |  |  | (139 | ) |  |  | (348 | )
Net cash provided by financing activities |  |  | 50 |  |  |  | 6,330 |
Effect of exchange rate on cash |  |  | (28 | ) |  |  | (16 | )
Net (decrease) increase in cash |  |  | (5,947 | ) |  |  | 7,455 |
Cash beginning of period |  |  | 26,307 |  |  |  | 18,891 |
Cash end of period |  | $ | 20,360 |  |  | $ | 26,346 |
Reconciliation of net loss to cash flow used by operating activities |  |  |  |  |  |  |  |
Net loss |  | $ | (20,108 | ) |  | $ | (2,891 | )
Adjustments to reconcile net loss to net cash (used in) operating activities: |  |  |  |  |  |  |  |
Depreciation expense |  |  | 596 |  |  |  | 540 |
Change in provision for doubtful accounts |  |  | (50 | ) |  |  | 12 |
Amortization of intangible assets |  |  | 1,678 |  |  |  | 653 |
Amortization of right-of-use assets - operating leases |  |  | 241 |  |  |  | 188 |
Amortization of right-of-use assets - finance leases |  |  | 13 |  |  |  | 8 |
Write-off of right-of-use asset |  |  | 111 |  |  |  | — |
Gain on remeasurement of fair value of equity interest in affiliate prior to acquisition |  |  | — |  |  |  | (6,138 | )
Impairment loss |  |  | 13,653 |  |  |  | — |
Equity in net loss of affiliate |  |  | — |  |  |  | 1,440 |
Stock-based compensation |  |  | 1,637 |  |  |  | 4,561 |
Gain on sale or disposal of property and equipment |  |  | (98 | ) |  |  | — |
Accounts receivable |  |  | 3,055 |  |  |  | (3,897 | )
Inventories |  |  | (1,090 | ) |  |  | (2,069 | )
Unbilled revenue |  |  | (30 | ) |  |  | (27 | )
Prepaid expense |  |  | 229 |  |  |  | (343 | )
Notes receivable |  |  | 75 |  |  |  | (251 | )
Deposits |  |  | (55 | ) |  |  | — |
VAT receivable |  |  | (8 | ) |  |  | 63 |
Accounts payable and accrued expenses |  |  | (4,645 | ) |  |  | 4,118 |
Operating lease liabilities |  |  | (277 | ) |  |  | (179 | )
Income taxes payable |  |  | 23 |  |  |  | 84 |
Contract liabilities |  |  | 62 |  |  |  | (7 | )
Liabilities from discontinued operations |  |  | — |  |  |  | (112 | )
Net cash used in operating activities |  | $ | (4,988 | ) |  | $ | (4,247 | )

See accompanying notes to unaudited condensed consolidated financial statements.

5

Table of Contents
NEXTPLAT CORP AND SUBSIDIARIES
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(Unaudited)

Unless the context requires otherwise, references to the “Company”, “we”, “us”, “our”, “our Company”, or “our business” refer to NextPlat Corp and its subsidiaries.

Note 1. Organization and Nature of Operations

NextPlat Corp:

NextPlat Corp, a Nevada corporation (the “Company”, “NextPlat”, “we”), formerly Orbsat Corp was incorporated in 1997. The Company operates two main e-commerce websites as well as 25 third-party e-commerce storefronts on platforms such as Alibaba, Amazon and Walmart. These e-commerce venues form an effective global network serving thousands of consumers, enterprises, and governments. Additionally, we provide a comprehensive array of Satellite Industry communication services and related equipment sales.

Our wholly-owned subsidiary, Global Telesat Communications Limited (“GTC”), was formed under the laws of England and Wales in 2008. On February 19, 2015, we entered into a share exchange agreement with GTC and all of the holders of the outstanding equity of GTC pursuant to which we acquired all of the outstanding equity in GTC.

Our wholly-owned subsidiary, Orbital Satcom Corp. (“Orbital Satcom”), a Nevada corporation, was formed on November 14, 2014.

On June 22, 2022, NextPlat B.V. (“NXPLBV”) was formed in Amsterdam, Netherlands, as a wholly owned subsidiary of NextPlat Corp. Presently, NXPLBV does not have any active operations.

On April 1, 2024, NextPlat acquired 100% of the ownership interest of Outfitter Satellite, Inc., a Tennessee corporation ("Outfitter") in a stock purchase transaction. Outfitter is a wholly-owned subsidiary of NextPlat Corp.

Progressive Care, LLC (formerly Progressive Care Inc.):

On April 12, 2024, the Company entered into a Merger Agreement and Plan of Reorganization (the “Merger Agreement”) with Progressive Care Inc. and Progressive Care LLC, a Nevada limited liability company and a direct, wholly owned subsidiary of the Company (“Progressive Care” or “Merger Sub”). On October 1, 2024 and pursuant to the terms of the Merger Agreement, the Company, Progressive Care Inc. and Merger Sub entered into a business combination transaction pursuant to which Progressive Care Inc. merged with and into Merger Sub (the “Merger”), with Merger Sub being the surviving entity of the Merger. Following the Merger, Progressive Care LLC became be a wholly-owned subsidiary of NextPlat. Progressive Care Inc. previously became a controlled subsidiary of the Company on July 1, 2023, therefore the Merger had no financial impact to the Company.

The Merger Agreement and the transactions contemplated thereby were negotiated and approved by a Special Committee comprised of three of the Company’s independent directors. The Merger Agreement was also approved by the entirety of the Company’s board of directors.

The Company’s shareholders approved the Merger at the Company’s annual meeting held on September 13, 2024.

Progressive Care, through its wholly-owned subsidiaries, Pharmco, LLC (“Pharmco 901”), Touchpoint RX, LLC doing business as Pharmco Rx 1002, LLC (“Pharmco 1002”), Family Physicians RX, Inc. doing business as PharmcoRx 1103 and PharmcoRx 1204 (“FPRX” or “Pharmco 1103” and “Pharmco 1204”) (pharmacy subsidiaries collectively referred to as “Pharmco”), and ClearMetrX Inc. (“ClearMetrX”) is a personalized healthcare services and technology company that provides prescription pharmaceuticals and risk and data management services to healthcare organizations and providers.

6

Table of Contents
NEXTPLAT CORP AND SUBSIDIARIES
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(Unaudited)

Pharmco 901 was formed on November 29, 2005 as a Florida Limited Liability Company and is a 100% owned subsidiary of Progressive Care. Pharmco 901 was acquired by Progressive on October 21, 2010. Progressive currently delivers prescriptions to Florida’s diverse population and ships medications to patients in states where they hold non-resident pharmacy licenses as well. Progressive currently holds Florida Community Pharmacy Permits at all Florida pharmacy locations and the Pharmco 901 location is licensed as a non-resident pharmacy in the following states: Arizona, Colorado, Connecticut, Georgia, Illinois, Minnesota, Nevada, New Jersey, New York, Pennsylvania, Texas, and Utah. Progressive is able to dispense to patients in the state of Massachusetts without a non-resident pharmacy license because Massachusetts does not require such a license for these activities.

Pharmco 1103 is a pharmacy with locations in North Miami Beach and Orlando, Florida that provides Pharmco’s pharmacy services to Miami-Dade County, Broward County, the Orlando/Tampa corridor, and the Treasure Coast of Florida. Progressive acquired all the ownership interests in Pharmco 1103 in a purchase agreement entered into on June 1, 2019.

Pharmco 1002 is a pharmacy located in Palm Springs, Florida that provides Pharmco’s pharmacy services to Palm Beach, St. Lucie and Martin Counties, Florida. Progressive acquired all the ownership interests in Pharmco 1002 in a purchase agreement entered into on July 1, 2018.

ClearMetrX was formed on June 10, 2020 and provides third-party administration (“TPA”) services to 340B covered entities. ClearMetrX also provides data analytics and reporting services to support and improve care management for health care organizations.

RXMD Therapeutics was formed on October 1, 2019. RXMD Therapeutics has had no operating activity to date.

Florida Sunshine Brands, LLC:

Florida Sunshine Brands, LLC (“Florida Sunshine”) is a Florida limited liability company and incorporated December 6, 2023. Florida Sunshine operates under an operating agreement between NextPlat, with a 51% ownership, and Outer Brands FS, LLC, with a 49% ownership. Florida Sunshine's main objective is to source and sell vitamins and nutritional supplements.

7

Table of Contents
NEXTPLAT CORP AND SUBSIDIARIES
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(Unaudited)

Note 2. Basis of Presentation and Principles of Consolidation

The accompanying Unaudited Condensed Consolidated Financial Statements of the Company have been prepared in accordance with accounting principles generally accepted in the United States (“GAAP”), consistent in all material respects with those applied in the 2023 Form 10-K, for interim financial information and in accordance with the rules and regulations of the SEC. Accordingly, they do not include all information and footnotes normally included in annual consolidated financial statements and should be read in conjunction with the consolidated financial statements and notes thereto included in the 2023 Form 10-K. In the opinion of management, the Condensed Consolidated Financial Statements contain all adjustments (consisting principally of normal recurring accruals) necessary for a fair presentation of the condensed consolidated balance sheets, statements of comprehensive (loss) income, statements of changes in equity, and statements of cash flows for such interim periods presented. Additionally, operating results for interim periods are not necessarily indicative of the results that can be expected for a full year. The year-end balance sheet data for comparative purposes was derived from audited consolidated financial statements.

The accompanying Unaudited Condensed Consolidated Financial Statements include the accounts of the Company and its subsidiaries. Intercompany transactions and balances have been eliminated in consolidation.

In the period ended September 30, 2024, the Company changed its presentation method on the statements of cash flows from the indirect method to the direct method. The Company has recast the Condensed Consolidated Statements of Cash Flows and related disclosures for the period ended September 30, 2023, to conform to the direct presentation method in the current period.

Business acquisition of Progressive Care, Inc.

On July 1, 2023, the Company, Charles M. Fernandez, Executive Chairman and Chief Executive Officer of the Company, and Rodney Barreto, Director of the Company, exercised common stock purchase warrants and were issued shares of Progressive Care common stock. After the exercise of the common stock purchase warrants, the Company and Messrs. Fernandez and Barreto collectively owned 53% of Progressive Care’s voting stock. At the time of exercise, all of the above common stock purchase warrants were in-the-money. Also on July 1, 2023, the Company and Messrs. Fernandez and Barreto entered into a voting agreement whereby at any annual or special shareholders meeting of Progressive Care’s stockholders, and whenever the holders of Progressive Care common stock act by written consent, Messrs. Fernandez and Barreto agreed to vote all of the Progressive Care common stock (including any new shares acquired after the date of the voting agreement or acquired through the conversion of securities convertible into Common Stock) that they own, directly or indirectly, in the same manner that NextPlat votes its common stock and equivalents. The voting agreement is irrevocable and perpetual in term.

The exercise of the stock options, along with the entry into the voting agreement, resulted in a change in control of Progressive Care under the voting interest model in Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (“ASC”) Topic 805, Business Combination, and was accounted for as a business acquisition. Therefore, Progressive Care became a consolidated subsidiary of the Company on July 1, 2023. The Company previously accounted for its equity interest in Progressive Care as an equity method investment. The consolidated results of operations for the period ended September 30, 2024, include the full nine months results of operations attributable to Progressive Care compared to the consolidated nine months ended September 30, 2023 which include only the three months results of operations attributable to Progressive Care due to Progressive Care becoming a consolidated subsidiary of the Company on July 1, 2023.

On April 12, 2024, NextPlat entered into a Merger Agreement and Plan of Reorganization (the “Merger Agreement”) with Progressive Care Inc, and Progressive Care LLC, a Nevada limited liability company and a direct, wholly owned subsidiary of NextPlat (“Merger Sub”). Pursuant to the terms of the Merger Agreement, upon the approval of NextPlat's and Progressive Care's shareholders, Progressive Care would merge with and into Merger Sub (the “Merger”), with Merger Sub being the surviving entity of the Merger. The result of which being that Progressive Care would become a wholly-owned subsidiary of NextPlat.

On September 13, 2024, the shareholders of each of NextPlat and Progressive Care approved the Merger Agreement and the transactions contemplated thereby.

On October 1, 2024, at 12:01 Eastern time, the Merger became effective and Progressive Care merged with and into Mergers Sub and thereby became a wholly owned subsidiary of NextPlat. In connection with the Merger, each share of Progressive Care common stock that was issued and outstanding immediately prior to the effective time of the Merger was converted into 1.4865 shares of NextPlat common stock, and each warrant to purchase Progressive Care common stock that was outstanding and unexercised immediately prior to the effective time of the Merger automatically converted into a warrant to purchase shares of NextPlat common stock with each such warrant having and being subject to the same terms and conditions (including vesting and exercisability terms) as were applicable to such Progressive Care warrant immediately before the effective time.

Business acquisition of Outfitter Satellite, Inc.

On March 25, 2024, the Company entered into a Stock Purchase Agreement with James T. McKinley, pursuant to which the Company agreed to purchase all of the issued and outstanding shares of common stock of Out fitter Satellite, Inc. (“Outfitter”). The closing of the transaction occurred on April 1, 2024. Outfitter is a wholly-owned subsidiary of NextPlat Corp.

Outfitter provides consumers, commercial and government customers, with advanced satellite-based connectivity solutions from leading brands, including Iridium, Inmarsat and Globalstar.

8

Table of Contents
NEXTPLAT CORP AND SUBSIDIARIES
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(Unaudited)

Use of Estimates

In preparing the Condensed Consolidated Financial Statements, management is required to make estimates and assumptions that affect the reported amounts of assets and liabilities as of the date of the statements of financial condition, and revenues and expenses for the periods then ended. Actual results may differ significantly from those estimates. Significant estimates made by management include, but are not limited to, assumptions used to calculate stock-based compensation, fair value of net assets acquired in the business combination with Progressive Care and Outfitter, common stock and options issued for services, net realizable value of accounts receivables and other receivables, the useful lives of property and equipment and intangible assets, the estimate of the fair value of the lease liability and related right of use assets, pharmacy benefit manager (“PBM”) fee estimates, and the estimates of the valuation allowance on deferred tax assets.

Note 3. Summary of Significant Accounting Policies

The significant accounting policies of the Company were described in Note 1 to the Audited Consolidated Financial Statements included in the Company’s Form 10-K for the fiscal year ended December 31, 2023. There have been no material changes to the Company’s significant accounting policies for the nine months ended September 30, 2024. Selected accounting policy disclosures are provided below.

Cash

The Company places its cash with high credit quality financial institutions. The Company’s account at these institutions are insured by the Federal Deposit Insurance Corporation (“FDIC”) up to $250,000. All cash amounts in excess of $250,000, approximately $1.0 million, are unsecured. The Company has a deposit placement agreement for Insured Cash Sweep Service (“ICS”). This service is a secure, and convenient way to access FDIC protection on large deposits, earn a return, and enjoy flexibility. The Company believes that the ICS agreement will mitigate its credit risk as it relates to uninsured FDIC amounts in excess of $250,000.

Foreign Currency Translation

The Company’s reporting currency is U.S. Dollars. The accounts of one of the Company’s subsidiaries, GTC, is maintained using the appropriate local currency, Great British Pound, as the functional currency. All assets and liabilities are translated into U.S. Dollars at balance sheet date, shareholders’ equity is translated at historical rates and revenue and expense accounts are translated at the average exchange rate for the year or the reporting period. The translation adjustments are reported as a separate component of stockholders’ equity, captioned as accumulated other comprehensive (loss) gain. Transaction gains and losses arising from exchange rate fluctuations on transactions denominated in a currency other than the functional currency are included in the condensed consolidated statements of comprehensive (loss) income.

The relevant translation rates are as follows: for the nine months ended September 30, 2024, closing rate at $1.31 US$: GBP, quarterly average rate at $1.30 US$: GBP, for the nine months ended September 30, 2023, closing rate at $1.23 US$: GBP, quarterly average rate at $1.26 US$: GBP, for the year ended December 31, 2023 closing rate at 1.27 US$: GBP, yearly average rate at 1.24 US$: GBP.

Unearned Revenue

Contract liabilities are shown separately in the condensed consolidated balance sheets as current liabilities. At September 30, 2024 and December 31, 2023, we had contract liabilities of approximately $104,000 and $42,000, respectively.

9

Table of Contents
NEXTPLAT CORP AND SUBSIDIARIES
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(Unaudited)

Direct and Indirect Remuneration (“DIR”) Fees

Progressive Care reports DIR fees as a reduction of revenue on the accompanying Condensed Consolidated Statements of Comprehensive (Loss) Income. DIR fees are fees charged by PBMs to pharmacies for network participation as well as periodic reimbursement reconciliations. The Company accrues an estimate of PBM fees, including DIR fees, which are assessed or expected to be assessed by payers at some point after adjudication of a claim, as a reduction of prescription revenue at the time revenue is recognized. Changes in the estimate of such fees are recorded as an adjustment to revenue when the change becomes known. Through December 31, 2023, for some PBMs, DIR fees were charged at the time of the settlement of a pharmacy claim. Other PBMs do not determine DIR fees at the claim settlement date, and therefore DIR fees are collected from pharmacies after claim settlement, often as clawbacks of reimbursements based on factors that vary from plan to plan. For example, two PBMs calculate DIR fees on a trimester basis and charge the Company for these fees as reductions of reimbursements paid to the Company two to three months after the end of the trimester (e.g., DIR fees for September - December 2023 claims were clawed back by these PBMs in May - June 2024). As of December 31, 2023, DIR fees that were not collected at the time of claim settlement, the Company recorded an accrued liability for estimated DIR fees that were fully collected by the PBMs by the end of the second quarter of 2024. Effective January 1, 2024, all PBMs began charging DIR fees at the time of the settlement of a pharmacy claim.

Recent Accounting Pronouncements

Accounting Pronouncements Issued but not yet Adopted

In November 2023, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) 2023-07, “Segment Reporting (Topic 280) - Improvements to Reportable Segment Disclosures” (“ASU 2023-07”), which improves reportable segment disclosure requirements, primarily through enhanced disclosures about significant expenses. ASU 2023-07 is required to be adopted for annual periods beginning after December 15, 2023, and interim period within fiscal years beginning after December 15, 2024, with early adoption permitted. The Company will adopt the standard in its interim reporting beginning with Q1-2025, and the Company will adopt the standard in its annual reporting for the year ending December 31, 2024. The Company expects that the adoption of the standard will not have a material impact on our consolidated financial statements but will enhance our current disclosures.

In December 2023, the FASB issued ASU 2023-09, “Income Taxes (Topic 740)—Improvements to Income Tax Disclosure” (“ASU 2023-09”), which establishes new income tax disclosure requirements in addition to modifying and eliminating certain existing requirements. ASU 2023-09 is required to be adopted for annual periods beginning after December 15, 2024, with early adoption permitted. The Company will adopt this accounting standard update effective January 1, 2025. The Company expects that the adoption of the standard will not have a material impact on our consolidated financial statements.

Other accounting standards that have been issued or proposed by FASB that do not require adoption until a future date are not expected to be relevant or have a material impact on the condensed consolidated financial statements upon adoption.

Subsequent Events

On October 1, 2024, the Company completed the Merger of Progressive Care, which Progressive Care became a wholly-owned subsidiary of the Company. See “Note 2. Basis of Presentation and Principles of Consolidation” for more details of the transaction.

On October 15, 2024, the Company settled its ongoing lawsuit with Mr. Thomas Seifert, the Company’s former Chief Financial Officer. Under the terms of the settlement, the Company agreed to pay to Mr. Seifert $150,000 and to reimburse him for legal costs in the amount of $600,000. In exchange, the Company and Mr. Seifert each agreed to dismiss the lawsuit with prejudice and to release the other party from all claims.

The Company has evaluated subsequent events through the date of this filing, the date the condensed consolidated financial statements were available to be issued.

10

Table of Contents
NEXTPLAT CORP AND SUBSIDIARIES
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(Unaudited)

Note 4. Fair Value

Accounting standards define fair value as the price that would be received from selling an asset or paid to transfer a liability in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants at the measurement date. Accounting standards establish a fair value hierarchy which requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value and also establishes the following three levels of inputs that may be used to measure fair value:

Level 1: Quoted prices in active markets for identical assets or liabilities.

Level 2: Inputs other than Level 1 that are observable, either directly or indirectly, such as quoted prices for similar assets or liabilities; quoted prices in markets that are not active; or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities.

Level 3: Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets and liabilities.

The following methods and assumptions were used by the Company in estimating fair value disclosures for financial instruments:

| ● | Cash, accounts receivable, and accounts payable and accrued liabilities: The amounts reported in the accompanying Condensed Consolidated Balance Sheets approximate fair value due to their short-term nature.

| ● | Notes payable and lease liabilities: The carrying amount of notes payable approximated fair value due to variable interest rates at customary terms and rates the Company could obtain in current financing. The carrying value of lease liabilities approximated fair value due to the implicit rate in the lease in relation to the Company’s borrowing rate and the duration of the leases (Level 2 inputs).

Identifiable Intangible Assets

The initial recognition of Progressive Care’s identifiable intangible assets, resulting from the acquisition on July 1, 2023 and the application of push-down accounting, were measured using Level 3 inputs. The fair value at the date of acquisition was approximately $14.7 million.

The initial recognition of the Outfitter identifiable intangible assets, resulting from the acquisition on April 1, 2024, were measured using Level 3 inputs. The fair value at the date of acquisition was approximately $0.6 million.

11

Table of Contents
NEXTPLAT CORP AND SUBSIDIARIES
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(Unaudited)

Note 5. Business Acquisition

On March 25, 2024, the Company entered into a Stock Purchase Agreement with James T. McKinley, pursuant to which the Company agreed to purchase all of the issued and outstanding shares of common stock of Out fitter. The closing of the transaction occurred on April 1, 2024.

Outfitter provides consumers, commercial and government customers, with advanced satellite-based connectivity solutions from leading brands, including Iridium, Inmarsat and Globalstar.

The following table summarizes the consideration transferred to acquire Outfitter and the amounts of identified assets acquired and liabilities assumed at the acquisition date (in thousands):

|  | Purchase Price Allocation |
Total purchase consideration |  | $ | 1,094 |
Identifiable net assets acquired - Provisional: |  |  |  |
Cash |  | $ | 236 |
Accounts receivable, net |  |  | 73 |
Inventory |  |  | 137 |
Prepaid expenses |  |  | 11 |
Property and equipment, net |  |  | 5 |
Right of use assets, net |  |  | 109 |
Intangible assets, net: |  |  |  |
Trade name (1) |  |  | 185 |
Customer records (2) |  |  | 415 |
Accounts payable and accrued expenses |  |  | (124 | )
Notes payable and accrued interest - current portion |  |  | (53 | )
Lease liabilities - current portion |  |  | (56 | )
Deferred tax liabilities (3) |  |  | (145 | )
Net assets acquired |  | $ | 793 |
Goodwill |  | $ | 301 |

(1) 10-year amortization period

(2) 5-year amortization period

( 3) Under federal tax law, previously unidentified finite lived intangible assets recognized from a business combination have no tax basis and therefore are not amortized for tax purposes. This tax position created a book/tax basis difference at April 1, 2024, the date of the business combination transaction. Therefore, an approximate $0.1 million deferred tax liability was recorded at April 1, 2024 as a result of the book/tax basis difference for the finite lived intangible assets.

The goodwill is attributable to the workforce of the acquired business and the significant synergies expected to arise after NextPlat’s acquisition of Outfitter. The goodwill is not deductible for tax purposes.

The initial recognition of Outfitter's identifiable intangible assets, resulting from the acquisition on April 1, 2024, were measured using Level 3 inputs. The fair value at the date of acquisition was approximately $0.6 million and were estimated by applying an income approach. The fair value estimates for the identifiable intangible assets are based on (1) an assumed discount rate of 37.3% (2) an assumed capitalization rate of 34.3% (3) assumed long-term growth rate of 3.0% (4) an assumed royalty rate of 1.8% (5) an assumed tax rate of 26.3% (6) an assumed risk free rate of 4.5% (7) an assumed equity risk premium of 6.5% (8) an assumed company specific risk premium rate of 22.5% (9) an assumed beta of 0.82.

12

Table of Contents
NEXTPLAT CORP AND SUBSIDIARIES
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(Unaudited)

Note 6. Revenue

The following table disaggregates net revenues by categories (in thousands):

|  | Three Months Ended September 30, |
|  | 2024 |  |  | 2023 |
Sales of products, net: |  |  |  |  |  |  |  |
e-Commerce revenue |  | $ | 3,834 |  |  | $ | 2,931 |
Pharmacy prescription and other revenue, net of PBM fees |  |  | 9,076 |  |  |  | 9,888 |
Sub total |  |  | 12,910 |  |  |  | 12,819 |
Revenues from services: |  |  |  |  |  |  |  |
Pharmacy 340B contract revenue |  |  | 2,457 |  |  |  | 2,471 |
Revenues, net |  | $ | 15,367 |  |  | $ | 15,290 |

|  | Nine Months Ended September 30, |
|  | 2024 |  |  | 2023 |
Sales of products, net: |  |  |  |  |  |  |  |
e-Commerce revenue |  | $ | 10,210 |  |  | $ | 8,764 |
Pharmacy prescription and other revenue, net of PBM fees |  |  | 30,922 |  |  |  | 9,888 |
Sub total |  |  | 41,132 |  |  |  | 18,652 |
Revenues from services: |  |  |  |  |  |  |  |
Pharmacy 340B contract revenue |  |  | 8,717 |  |  |  | 2,471 |
Revenues, net |  | $ | 49,849 |  |  | $ | 21,123 |

13

Table of Contents
NEXTPLAT CORP AND SUBSIDIARIES
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(Unaudited)

Note 7. Loss per Share

Net income (loss) per common share is calculated in accordance with ASC Topic 260: Earnings per Share (“ASC 260”). Basic income (loss) per share is computed by dividing net income (loss) by the weighted average number of shares of common stock outstanding during the period. The computation of diluted net loss per share does not include dilutive common stock equivalents in the weighted average shares outstanding as they would be anti-dilutive. In periods where the Company has a net loss, all dilutive securities are excluded.

The components of basic and diluted EPS were as follows (in thousands, except per share data).

|  | Three Months Ended September 30, |  |  | Nine Months Ended September 30, |
|  | 2024 |  |  | 2023 |  |  | 2024 |  |  | 2023 |
Net (loss) income attributable to NextPlat Corp common shareholders |  | $ | (4,216 | ) |  | $ | 3,448 |  |  | $ | (11,008 | ) |  | $ | (2,080 | )
Basic weighted average common shares outstanding |  |  | 18,982 |  |  |  | 18,703 |  |  |  | 18,844 |  |  |  | 17,079 |
Potentially dilutive common shares |  |  | — |  |  |  | 1,607 |  |  |  | — |  |  |  | — |
Diluted weighted average common shares outstanding |  |  | 18,982 |  |  |  | 20,310 |  |  |  | 18,844 |  |  |  | 17,079 |
Weighted average (loss) earnings per common share - basic |  | $ | (0.22 | ) |  | $ | 0.18 |  |  |  | (0.58 | ) |  | $ | (0.12 | )
Weighted average (loss) earnings per common share - diluted |  | $ | (0.22 | ) |  | $ | 0.17 |  |  | $ | (0.58 | ) |  | $ | (0.12 | )
Potentially dilutive common shares excluded from the calculation of diluted weighted average (loss) earnings per common share: |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Stock options |  |  | 7 |  |  |  | 232 |  |  |  | 38 |  |  |  | 162 |
Common stock purchase warrants |  |  | — |  |  |  | 1,375 |  |  |  | — |  |  |  | 876 |
|  |  | 7 |  |  |  | 1,607 |  |  |  | 38 |  |  |  | 1,038 |

Note 8. Accounts Receivable

Accounts receivable consisted of the following (in thousands):

|  | September 30, 2024 |  |  | December 31, 2023 |
Gross accounts receivable – trade |  | $ | 6,734 |  |  | $ | 9,195 |
Less: allowance for doubtful accounts |  |  | (159 | ) |  |  | (272 | )
Accounts receivable – trade, net |  | $ | 6,575 |  |  | $ | 8,923 |

The Company decreased the allowance for credit losses in the amount of approximately $0.1 million and $12,000 for the nine months ended September 30, 2024 and 2023, respectively.

Accounts receivable – trade, net for the Company as of January 1, 2023 and September 30, 2023 were approximately $0.4 million and $7.8 million, respectively.

14

Table of Contents
NEXTPLAT CORP AND SUBSIDIARIES
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(Unaudited)

Note 9. Inventory

Inventory consisted of the following (in thousands):

|  | September 30, 2024 |  |  | December 31, 2023 |
Finished goods |  | $ | 6,448 |  |  | $ | 5,195 |
Less reserve for obsolete inventory |  |  | (86 | ) |  |  | (60 | )
Total |  | $ | 6,362 |  |  | $ | 5,135 |

Note 10. Property and Equipment, net

Property and equipment, net consisted of the following (in thousands):

|  | September 30, 2024 |  |  | December 31, 2023 |
Appliques |  | $ | 2,160 |  |  | $ | 2,160 |
Building |  |  | 2,116 |  |  |  | 2,116 |
Vehicles |  |  | 674 |  |  |  | 595 |
Website development |  |  | 618 |  |  |  | 587 |
Office furniture and fixtures |  |  | 556 |  |  |  | 527 |
Land |  |  | 184 |  |  |  | 184 |
Leasehold improvements |  |  | 177 |  |  |  | 124 |
Computer equipment |  |  | 123 |  |  |  | 117 |
Rental equipment |  |  | 88 |  |  |  | 60 |
Construction in progress |  |  | — |  |  |  | 22 |
Property and equipment gross |  |  | 6,696 |  |  |  | 6,492 |
Less: accumulated depreciation |  |  | (3,101 | ) |  |  | (2,503 | )
Property and equipment, net |  | $ | 3,595 |  |  | $ | 3,989 |

Depreciation expense was approximately $0.6 million and $0.5 million for the nine months ended September 30, 2024 and 2023, respectively.

15

Table of Contents
NEXTPLAT CORP AND SUBSIDIARIES
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(Unaudited)

Note 11. Goodwill and Intangible Assets, net

Goodwill

During the nine months ended September 30, 2024, the Company concluded that the carrying amount of the Healthcare Operations reporting segment exceeded its fair value, resulting in the recognition of a non-cash goodwill impairment charge of approximately $0.7 million. An interim impairment assessment was considered necessary as a result of the sustained decline in the Healthcare Operations stock price and related market capitalization. The goodwill impairment charge is reflected in Impairment loss in the Condensed Consolidated Statements of Comprehensive (Loss) Income. With the assistance of a third-party valuation firm, the fair value of the Healthcare Operations reporting segment was determined using an income approach whereby the fair value was calculated utilizing discounted estimated future cash flows (level 3 nonrecurring fair value measurement). The income approach requires several assumptions including estimation of future cash flows, which is dependent on internally-developed forecasts of revenue and profitability, estimation of the long-term rate of growth for the business, estimation of the useful life over which cash flows will occur, and determination of the weighted average cost of capital, which is risk-adjusted to reflect the specific risk profile of the reporting unit. The long-term growth rate used in the impairment was 3.0% and the weighted average cost of capital used in the impairment was 13.5%.

The following table reflects changes in the carrying amount of goodwill during the periods presented by reportable segments (in thousands):

|  | e-Commerce Operations |  |  | Healthcare Operations |  |  | Total |
Goodwill, net as of December 31, 2023 |  | $ | — |  |  | $ | 731 |  |  | $ | 731 |
Changes in Goodwill during the period ended September 30, 2024: |  |  |  |  |  |  |  |  |  |  |  |
Goodwill acquired - Outfitter acquisition |  |  | 301 |  |  |  | — |  |  |  | 301 |
Deferred tax effect of intangible basis difference (1) |  |  | (145 | ) |  |  | — |  |  |  | (145 | )
Impairment loss |  |  | — |  |  |  | (731 | ) |  |  | (731 | )
Goodwill, net as of September 30, 2024 |  | $ | 156 |  |  | $ | — |  |  | $ | 156 |

(1) Decrease related to book tax basis difference of intangible assets arising for the business acquisition of Outfitter.

16

Table of Contents
NEXTPLAT CORP AND SUBSIDIARIES
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(Unaudited)

Intangibles

During the nine months ended September 30, 2024, the Company performed an impairment assessment of long-lived assets as it relates to the Healthcare Operations reporting segment due to the decline in future projected revenues and cash flows. As a result, the Company completed a recoverability test and concluded that the asset groups were not fully recoverable as the undiscounted expected future cash flows did not exceed their carrying amounts. The Company, with the assistance of a third-party valuation firm, determined the fair value of the asset groups using an income approach utilizing undiscounted estimated future cash flows (level 3 nonrecurring fair value measurement). The income approach requires several assumptions including estimation of future cash flows, which is dependent on internally-developed forecasts of revenue and profitability, and estimation of the useful life over which cash flows will occur. The carrying amount of certain assets in the asset group exceeded the fair value, resulting in the recognition of a non-cash impairment charge to intangible assets of approximately $12.8 million for the nine months ended September 30, 2024 (reflected in Impairment loss in the Condensed Consolidated Statements of Comprehensive (Loss) Income).

Intangible assets, net consisted of the following (in thousands):

|  | September 30, 2024 |
|  | Gross amount |  |  | Accumulated amortization |  |  | Net amount |
Trade names |  | $ | 185 |  |  | $ | (10 | ) |  | $ | 175 |
Customer contracts |  |  | 665 |  |  |  | (285 | ) |  |  | 380 |
Total intangible assets |  | $ | 850 |  |  | $ | (295 | ) |  | $ | 555 |

|  | December 31, 2023 |
|  | Gross amount |  |  | Accumulated amortization |  |  | Net amount |
Pharmacy records |  | $ | 8,130 |  |  | $ | (807 | ) |  | $ | 7,323 |
Trade names |  |  | 4,700 |  |  |  | (224 | ) |  |  | 4,476 |
Developed technology |  |  | 2,880 |  |  |  | (281 | ) |  |  | 2,599 |
Customer contracts |  |  | 250 |  |  |  | (225 | ) |  |  | 25 |
Total intangible assets |  | $ | 15,960 |  |  | $ | (1,537 | ) |  | $ | 14,423 |

17

Table of Contents
NEXTPLAT CORP AND SUBSIDIARIES
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(Unaudited)

A summary of the changes to the gross carrying amount, accumulated amortization, and net book value of total intangible assets by reporting unit during the nine months ended September 30, 2024 were as follows (in thousands):

|  | e-Commerce Operations |  |  | Healthcare Operations |  |  | Total |
Balances at December 31, 2023: |  |  |  |  |  |  |  |  |  |  |  |
Gross amount |  | $ | 250 |  |  | $ | 15,710 |  |  | $ | 15,960 |
Accumulated amortization |  |  | (225 | ) |  |  | (1,312 | ) |  |  | (1,537 | )
Net amount |  |  | 25 |  |  |  | 14,398 |  |  |  | 14,423 |
Changes during the nine months ended September 30, 2024: |  |  |  |  |  |  |  |  |  |  |  |
Outfitter acquisition |  |  | 600 |  |  |  | — |  |  |  | 600 |
Accumulated amortization expense |  |  | (70 | ) |  |  | (1,608 | ) |  |  | (1,678 | )
Impairment - gross amount |  |  | — |  |  |  | (15,710 | ) |  |  | (15,710 | )
Impairment - accumulated amortization |  |  | — |  |  |  | 2,920 |  |  |  | 2,920 |
Net amount |  |  | 530 |  |  |  | (14,398 | ) |  |  | (13,868 | )
Balances at September 30, 2024: |  |  |  |  |  |  |  |  |  |  |  |
Gross amount |  |  | 850 |  |  |  | — |  |  |  | 850 |
Accumulated amortization |  |  | (295 | ) |  |  | — |  |  |  | (295 | )
Net amount |  | $ | 555 |  |  | $ | — |  |  | $ | 555 |

For the nine months ended September 30, 2024 and 2023, the Company recognized amortization expense of approximately $1.7 million and $0.7 million, respectively.

The following table represents the total estimated future amortization of intangible assets for the five succeeding years and thereafter as of September 30, 2024 (in thousands):

Year |  |  | Amount |
2024 (remaining three months) |  | $ | 32 |
2025 |  |  | 102 |
2026 |  |  | 102 |
2027 |  |  | 102 |
2028 |  |  | 102 |
Thereafter |  |  | 115 |
Total |  | $ | 555 |

18

Table of Contents
NEXTPLAT CORP AND SUBSIDIARIES
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(Unaudited)

Note 12. Accounts Payable and Accrued Expenses

Accounts payable and accrued expenses consisted of the following (in thousands):

|  | September 30, 2024 |  |  | December 31, 2023 |
Accounts payable |  | $ | 7,803 |  |  | $ | 12,142 |
Accrued wages and payroll liabilities |  |  | 449 |  |  |  | 200 |
Accrued other liabilities |  |  | 158 |  |  |  | 187 |
Customer deposits payable |  |  | 121 |  |  |  | 76 |
Accrued PBM fees |  |  | — |  |  |  | 571 |
Total |  | $ | 8,531 |  |  | $ | 13,176 |

Note 13. Notes Payable

Notes payable consisted of the following (in thousands):

|  | September 30, 2024 |  |  | December 31, 2023 |
A. Mortgage note payable - commercial bank - collateralized |  | $ | 1,073 |  |  | $ | 1,140 |
B. Note payable - uncollateralized |  |  | 25 |  |  |  | 25 |
C. Notes payable - collateralized |  |  | 279 |  |  |  | 255 |
Insurance premiums financing |  |  | 164 |  |  |  | 103 |
Subtotal |  |  | 1,541 |  |  |  | 1,523 |
Less: current portion of notes payable |  |  | (461 | ) |  |  | (312 | )
Long-term portion of notes payable |  | $ | 1,080 |  |  | $ | 1,211 |

19

Table of Contents
NEXTPLAT CORP AND SUBSIDIARIES
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(Unaudited)

(A) Mortgage Note Payable – collateralized

In 2018, Progressive Care closed on the purchase of land and building located at 400 Ansin Boulevard, Hallandale Beach, Florida. The purchase price was financed in part through a mortgage note and security agreement entered into with a commercial lender in the amount of $1,530,000. The promissory note is collateralized by the land and building, bears interest at a fixed rate of 4.75% per annum, matures on December 14, 2028 and is subject to a prepayment penalty. Principal and interest will be repaid through 119 regular payments of $11,901 that began in January 2019, with the final payment of all principal and accrued interest not yet paid on December 14, 2028. Note repayment is guaranteed by Progressive Care Inc.

(B) Note Payable – Uncollateralized

As of September 30, 2024 the uncollateralized note payable represents a non-interest-bearing loan that is due on demand from an investor.

(C) Notes Payable – Collateralized

On July 16, 2020 (the “Issue Date”), GTC, entered into a Coronavirus Interruption Loan Agreement (“Debenture”) by and among the Company and HSBC UK Bank PLC (the “Lender”) for an amount of £250,000, or USD $338,343 at an exchange rate of GBP: USD of 1.3533720. The Debenture bears interest beginning July 16, 2021, at a rate of 4.0% per annum over the Bank of England Base Rate (0.1% as of July 16, 2020), payable monthly on the outstanding principal amount of the Debenture. The Debenture has a term of 6 years from the date of drawdown, July 15, 2026, the “Maturity Date”. The first repayment of £4,166.67 (exclusive of interest) was made 13 month(s) after July 16, 2020. Voluntary prepayments are allowed with 5 business days’ written notice and the amount of the prepayment is equal to 10% or more of the limit or, if less, the balance of the debenture. The Debenture is secured by all GTC’s assets as well as a guarantee by the UK government. The proceeds from the Debenture were used for general corporate and working capital purposes. The Debenture includes customary events of default, including, among others: (i) non-payment of amounts due thereunder, (ii) non-compliance with covenants thereunder, (iii) bankruptcy or insolvency (each, an “Event of Default”). Upon the occurrence of an Event of Default, the Debenture becomes payable upon demand.

In April 2021, Progressive Care entered into a note obligation with a commercial lender, the proceeds from which were used to purchase pharmacy equipment in the amount of approximately $30,000. During September 2021, pharmacy equipment was returned since the installation was cancelled and the note was amended. The amended promissory note payable requires 46 monthly payments of $331, including interest at 6.9%. The balance outstanding as of September 30, 2024 and December 31, 2023 on the note payable was approximately $3,000 and $6,000, respectively.

In July 2022, Progressive Care entered into a note obligation with a commercial lender, the proceeds from which were used to purchase pharmacy equipment in the amount of approximately $90,000. The terms of the promissory note payable require 60 monthly payments of $1,859, including interest at 8.78% starting January 2023. The balance outstanding on the note payable was approximately $62,000 and $71,000 as of September 30, 2024 and December 31, 2023, respectively.

In September 2022, Progressive Care entered into a note obligation with a commercial lender, the proceeds from which were used to purchase a vehicle in the amount of approximately $25,000. The terms of the promissory note payable require 24 monthly payments of $1,143, including interest at 8.29% starting October 2022. The note was paid in full as of September 30, 2024. The balance outstanding on the note payable was approximately $10,000 as of December 31, 2023.

20

Table of Contents
NEXTPLAT CORP AND SUBSIDIARIES
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(Unaudited)

Principal outstanding as of September 30, 2024, is expected to be repayable as follows (in thousands):

Year |  | Amount |
2024 (remaining three months) |  | $ | 163 |
2025 |  |  | 343 |
2026 |  |  | 158 |
2027 |  |  | 124 |
2028 |  |  | 753 |
Thereafter |  |  | — |
Total |  | $ | 1,541 |

Note 14. Equity

Stock-based compensation expense is recorded in selling, general and administrative expense in the Condensed Consolidated Statements of Comprehensive (Loss) Income. For the nine months ended September 30, 2024 and 2023, stock-based compensation expense was approximately $1.6 million and $4.6 million, respectively. There were no income tax benefits recognized from stock-based compensation during the nine months ended September 30, 2024 and 2023 due to cumulative losses and valuation allowances.

Preferred Stock

We have authorized 3,333,333 shares of $0.0001 par value of preferred stock. As of September 30, 2024 and December 31, 2023 there were no shares of preferred stock issued and outstanding.

Common Stock

We have authorized 50,000,000 shares of $0.0001 par value common stock. As of September 30, 2024, 18,993,146 shares of common stock were issued and outstanding.

Listing on the Nasdaq Capital Market

Our common stock and warrants have been trading on the Nasdaq Capital Market under the symbols “NXPL” and “NXPLW,” respectively, since January 21, 2022. Prior to January 21, 2022, our common stock and warrants were traded on the Nasdaq Capital Market under the symbols “OSAT” and “OSATW,” respectively.

April 2023 Private Placement of Common Stock

On April 5, 2023, the Company entered into a securities purchase agreement (the “Purchase Agreement”) with an accredited investor (the “Investor”) for the sale by the Company in a private placement of 3,428,571 shares of the Company’s common stock, $0.0001 par value per share (the “Common Stock”). The offering price of the Common Stock was $1.75 per share, the closing price of the Common Stock on April 4, 2023. On April 11, 2023, the Private Placement closed. Upon the closing of the Private Placement, the Company received gross proceeds of approximately $6.0 million. The Company sold the Common Stock to the Investor in reliance on the exemption from registration afforded by Section 4(a)(2) of the Securities Act and Rule 506 of Regulation D promulgated under the Securities Act and corresponding provisions of state securities or “blue sky” laws. The Investor represented that it is acquiring the Common Stock for investment only and not with a view towards, or for resale in connection with, the public sale or distribution thereof. Accordingly, the Common Stock has not been registered under the Securities Act and may not be offered or sold in the United States absent registration or an exemption from registration under the Securities Act and any applicable state securities laws.

21

Table of Contents
NEXTPLAT CORP AND SUBSIDIARIES
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(Unaudited)

Note 15. Related Party Transactions

Progressive Care Inc.

Following the consummation of the Company’s investment in Progressive Care Inc. on September 2, 2022, our Chairman and Chief Executive Officer, Charles M. Fernandez, and our board member, Rodney Barreto, were appointed to Progressive Care’s Board of Directors, with Mr. Fernandez appointed to serve as Chairman of Progressive Care’s Board of Directors and Mr. Barreto appointed to serve as a Vice Chairman of Progressive Care’s Board of Directors. On November 11, 2022, the Progressive Care board of directors elected Mr. Fernandez as the Chief Executive Officer of Progressive Care. In addition, on September 2, 2022, NextPlat, Messrs. Fernandez and Barreto and certain other purchasers purchased from Iliad Research and Trading, L.P. (“Iliad”) a Secured Convertible Promissory Note, dated March 6, 2019, made by Progressive Care to Iliad (the “Note”). The accrued and unpaid principal and interest under the note at the time of the purchase was approximately $2.8 million. The aggregate purchase price paid to Iliad for the Note was $2.3 Million of which NextPlat contributed $1.0 million and Messrs. Fernandez and Barreto contributed $400,000 each (the “Note Purchase”). In connection with the Note Purchase, NextPlat, Messrs. Fernandez and Barreto and the other purchasers of the Note entered into a Debt Modification Agreement with Progressive Care. In consideration of the concessions in the Debt Modification Agreement, Progressive Care issued 105,000 shares of its common stock to the purchasers of the Note, of which NextPlat, Charles Fernandez and Rodney Barreto, received 45,653, 18,261, and 18,261 shares, respectively, in each case after giving effect to a 1-for-200 reverse stock split enacted by Progressive Care on December 30, 2022.

On February 1, 2023, the Company entered into a Management Services Agreement with Progressive Care to provide certain management and administrative services to Progressive Care for a $25,000 per month fee. During May 2023 the management fee was reduced to $20,000 per month. During the nine months ended September 30, 2023, the Company received approximately $175,000 from Progressive Care as management fees. The management fees in the amount of approximately $180,000 for the nine months ended September 30, 2024 are eliminated as a result of the Progressive Care consolidation as of July 1, 2023.

On May 5, 2023, the Company entered into a Securities Purchase Agreement with Progressive Care, pursuant to which the Company agreed to purchase 455,000 newly issued Units of securities from Progressive Care at a price per Unit of $2.20 for an aggregate purchase price of $1.0 million (the “Unit Purchase”). Each Unit consists of one share of Progressive Care common stock, par value $0.0001 per share, and one common stock purchase warrant to purchase a share of Progressive Care common Stock (the “PIPE Warrants”)

On May 9, 2023, pursuant to the Debt Conversion Agreement (“DCA”), the Company received 570,599 shares of Progressive Care common stock, Charles M. Fernandez received 228,240 shares of Progressive Care common stock, and Rodney Barreto received 228,240 shares of Progressive Care common stock. To induce the approval of the debt conversion pursuant to the DCA, Messrs. Fernandez and Barreto received Inducement Warrants to purchase 190,000 and 30,000 shares of Progressive Care common stock, respectively. In addition, the Company and Messrs. Fernandez and Barreto also received a common stock purchase warrant to purchase one share of Progressive Care common stock for each share of Progressive Care common stock they received upon conversion of the Note.

22

Table of Contents
NEXTPLAT CORP AND SUBSIDIARIES
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(Unaudited)

On July 1, 2023, the Company, Charles M. Fernandez, and Rodney Barreto exercised common stock purchase warrants and were issued shares of Progressive Care common stock. The Company exercised common stock purchase warrants on a cashless basis and was issued 402,269 shares of Progressive Care common stock. The Company also exercised common stock purchase warrants on a cash basis and paid consideration in the amount of $506,000 and was issued 230,000 shares of Progressive Care common stock. Mr. Fernandez exercised common stock purchase warrants on a cashless basis and was issued 211,470 shares of Progressive Care common stock. Mr. Barreto exercised common stock purchase warrants on a cashless basis and was issued 130,571 shares of Progressive Care common stock. After the exercise of the warrants, NextPlat and Messrs. Fernandez and Barreto collectively owned approximately 53% of Progressive Care’s voting stock.

Also, on July 1, 2023, NextPlat and Messrs. Fernandez and Barreto, entered into a voting agreement whereby at any annual or special shareholders meeting of Progressive Care’s stockholders, and whenever the holders of Progressive Care’s common stock act by written consent, Messrs. Fernandez and Barreto agreed to vote all of the shares of Progressive Care common stock (including any new shares acquired after the date of the voting agreement or acquired through the conversion of securities convertible into Progressive Care common stock) that they own, directly or indirectly, in the same manner that NextPlat votes its shares of Progressive Care common stock. The voting agreement is irrevocable and perpetual in term.

Next Borough Capital Fund, LP.

On July 7, 2023, the Company entered into an unsecured promissory note agreement with Next Borough Capital Management, LLC (“the Borrower”), whereby the Company loaned $250,000 to the Borrower. The note bears interest at an annual rate of 7%. The outstanding principal balance of the note plus all accrued unpaid interest was due and payable on July 7, 2024, the Maturity Date. The Maturity Date was extended until November 8, 2024, which the note was paid in full. Each of the Company, Charles M. Fernandez, Robert D. Keyser, Jr., eAperion Partners, LLC, and a revocable trust of Rodney Barreto are members of the Borrower. The net realizable value of the note as of September 30, 2024 was approximately $206,000, net of an allowance of approximately $63,000. The balance as of December 31, 2023 was approximately $256,000. The note is recorded in Notes receivable due from related party in the Condensed Consolidated Balance Sheets.

Other

On July 12, 2022, the Company hired Lauren Sturges Fernandez, the spouse of Mr. Fernandez, as Manager of Digital Assets. Mrs. Fernandez is an at-will employee with an annual salary of $95,000. On September 22, 2022, Mrs. Fernandez’s title was changed to Chief of Staff and Special Assistant to the Chairman of the Board, with no change to her salary. Previously Mrs. Fernandez was a consultant and earned compensation for her services of $10,995 for the year ended December 31, 2022. In April 2023, Mrs. Fernandez’s annual salary increased to $125,000, which was approved by the Board of Directors.

Note 16. Commitments and Contingencies

Litigation

On June 22, 2021, Thomas Seifert’s employment as the Company’s Chief Financial Officer was terminated for cause. Mr. Seifert asserts that the termination was not for cause and that he is owed compensation payable under his June 2, 2021 employment agreement. The Company’s position is that Mr. Seifert is not owed any additional compensation relating to his prior service with the Company or arising under any employment agreement. The Company and Mr. Seifert are currently engaged in litigation over the matter of his employment and termination. The Company believes it has adequate defenses to Mr. Seifert’s claims and has asserted affirmative claims for relief against Mr. Seifert including, but not limited to, breach of the employment agreement, breach of his fiduciary duties, fraud in the inducement in connection with the employment agreement, fraudulent misrepresentation, and constructive fraud. A detailed recitation of the Company’s factual allegations supporting these claims can be found in the Company’s Second Amended Complaint, filed June 21, 2022. Subsequent to September 30, 2024, the Company settled with Mr. Seifert on October 15, 2024. Under the terms of the settlement, the Company agreed to pay to Mr. Seifert $150,000 and to reimburse him for legal costs in the amount of $600,000. In exchange, the Company and Mr. Seifert each agreed to dismiss the lawsuit with prejudice and to release the other party from all claims.

On June 17, 2024, Progressive Care was notified of a potential claim by a former employee who allegedly suffered a loss due to an alleged breach by Progressive Care of such former employee's employment contract. Management believes, based on discussions with its legal counsel, that Progressive Care has meritorious defenses against the former employee’s claim. Since receipt of the notice of the claim, Progressive Care filed a petition for arbitration against the former employee, asserting that it was the employee who breached the employment contract. Progressive Care will prosecute its claims and will defend any counterclaims vigorously as Progressive Care believes it will prevail on the merits. At this time, we cannot reasonably estimate the amount of the loss.

From time to time, the Company may become involved in litigation relating to claims arising out of our operations in the normal course of business. The Company is not currently involved in any pending legal proceeding or litigation, and, to the best of our knowledge, no governmental authority is contemplating any proceeding to which the Company is a party or to which any of the Company’s properties is subject, which would reasonably be likely to have a material adverse effect on the Company’s business, financial condition and operating results.

23

Table of Contents
NEXTPLAT CORP AND SUBSIDIARIES
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(Unaudited)

Note 17. Leases

The Company has entered into a number of lease arrangements under which the Company is the lessee. These leases are classified as operating leases. In addition, the Company has elected the short-term lease practical expedient in ASC Topic 842 related to real estate leases with terms of one year. The following is a summary of the Company’s lease arrangements.

Finance Lease Agreements

In May 2018, Progressive Care entered into a finance lease obligation to purchase pharmacy equipment with a cost of approximately $115,000. The terms of the lease agreement require monthly payments of $1,678 plus applicable tax over 84 months ending March 2025 including interest at the rate of 6%.

Operating Lease Agreements

Right-of-use (“ROU”) assets for operating leases are periodically reduced by impairment losses. We use the long-lived assets impairment guidance in ASC Subtopic 360-10, Property, Plant, and Equipment – Overall, to determine whether an ROU asset is impaired, and if so, the amount of the impairment loss to recognize. As of September 30, 2024 and December 31, 2023, we have recognized impairment losses for ROU assets of approximately $0.1 million and $0, respectively.

We monitor for events or changes in circumstances that require a reassessment of one of our leases. When a reassessment results in the re-measurement of a lease liability, a corresponding adjustment is made to the carrying amount of the corresponding ROU asset unless doing so would reduce the carrying amount of the ROU asset to an amount less than zero. In that case, the amount of the adjustment that would result in a negative ROU asset balance is recorded in profit or loss.

On December 2, 2021, NextPlat entered into a 62-month lease for 4,141 square feet of office space in Florida (“Florida Lease”), for $186,345 annually. The rent increases 3% annually. The Florida Lease commenced upon occupancy on June 13, 2022, and will expire on August 31, 2027. The Florida Lease does not require any contingent rental payments, impose any financial restrictions, or contain any residual value guarantees. Variable expenses generally represent the Company’s share of the landlord’s operating expenses.

For our facilities in Poole, England, we rent office and warehouse space of approximately 2,660 square feet for £30,000 annually or approximately USD $37,107, based on a yearly average exchange rate of 1.24 GBP: USD. The Poole lease was renewed on October 6, 2022, which expired October 31, 2023 and was renewed for an additional twelve months. On August 1, 2024 we relocated from our previous location in Poole, England to a new facility in Poole and entered into a new lease for office and warehouse space. This is a three-year lease and expires on July 31, 2027. The annual rent is approximately £14,000 through July 31, 2025, approximately £30,000 through July 31, 2026, and approximately £26,000 through July 31, 2027.

Progressive Care entered into a lease agreement for its Orlando pharmacy in August 2020. The term of the lease is 66 months with a termination date of February 2026. The lease agreement calls for monthly payments that began in February 2021, of $4,310, with an escalating payment schedule each year thereafter.

Progressive Care leases its North Miami Beach pharmacy location under an operating lease agreement with a lease commencement date in September 2021. The term of the lease is 60 months with a termination date in August 2026. The lease calls for monthly payments of $5,237, with an escalating payment schedule each year thereafter.

24

Table of Contents
NEXTPLAT CORP AND SUBSIDIARIES
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(Unaudited)

Progressive Care also leases its Palm Beach County pharmacy locations under operating lease agreements expiring in February 2025.

In June 2023, NextPlat entered into a 36-months lease to lease twenty-five (25) hours in a Phenom 300 aircraft, for approximately $200,650 annually. The rent increases 3% annually. The lease commenced on June 7, 2023. In June 2024, NextPlat terminated the lease and paid a lease termination fee in the amount of $0.1 million. The remaining carrying value, net of the ROU asset and liability in the amount of $0.1 million, was written off and recorded in selling, general and administrative expense on the Condensed Consolidated Statements of Comprehensive (Loss) Income.

Note 18. Reportable Segments

The Company has two reportable segments: (i) e-Commerce Operations, which involves acquiring and leasing, primarily an e-commerce platform to collaborate with businesses to optimize their ability to sell their goods online, domestically, and internationally, and enabling customers and partners to optimize their e-commerce presence and revenue, and other related businesses and (ii) Healthcare Operations, which provides third party administrator (TPA), data management, COVID-19 related diagnostics and vaccinations, prescription pharmaceuticals, compounded medications, telepharmacy services, anti-retroviral medications, medication therapy management, the supply of prescription medications to long-term care facilities, medication adherence packaging, contracted pharmacy services for 340B covered entities under the 340B Drug Discount Pricing Program, and health practice risk management.

The Company evaluates the performance of each of the segments based on profit or loss after general and administrative expenses. While the Company believes there are synergies between the two business segments, the segments are managed separately because each requires different business strategies.

The following tables present a summary of the reportable segments (in thousands):

For the Three Months Ended September 30, 2024 |  | e-Commerce Operations |  |  | Healthcare Operations |  |  | Eliminations |  |  | Total |
Pharmacy prescription and other revenue, net of PBM fees |  | $ | — |  |  | $ | 9,076 |  |  | $ | — |  |  | $ | 9,076 |
e-Commerce revenue |  |  | 3,834 |  |  |  | — |  |  |  | — |  |  |  | 3,834 |
Pharmacy 340B contract revenue |  |  | — |  |  |  | 2,457 |  |  |  | — |  |  |  | 2,457 |
Revenues, net |  | $ | 3,834 |  |  | $ | 11,533 |  |  | $ | — |  |  | $ | 15,367 |
Expenses: |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Cost of revenue |  |  | 2,756 |  |  |  | 9,091 |  |  |  | — |  |  |  | 11,847 |
Selling, general and administrative |  |  | 969 |  |  |  | 1,384 |  |  |  | (60 | ) |  |  | 2,293 |
Salaries, wages and payroll taxes |  |  | 617 |  |  |  | 2,258 |  |  |  | — |  |  |  | 2,875 |
Impairment loss |  |  | — |  |  |  | 3,729 |  |  |  | — |  |  |  | 3,729 |
Professional fees |  |  | 1,481 |  |  |  | 663 |  |  |  | — |  |  |  | 2,144 |
Depreciation and amortization |  |  | 141 |  |  |  | 337 |  |  |  | — |  |  |  | 478 |
Total expenses |  |  | 5,964 |  |  |  | 17,462 |  |  |  | (60 | ) |  |  | 23,366 |
Loss before other (income) expense |  |  | (2,130 | ) |  |  | (5,929 | ) |  |  | 60 |  |  |  | (7,999 | )
Other income |  |  | (324 | ) |  |  | (116 | ) |  |  | 60 |  |  |  | (380 | )
Loss before income taxes |  |  | (1,806 | ) |  |  | (5,813 | ) |  |  | — |  |  |  | (7,619 | )
Income taxes |  |  | (45 | ) |  |  | — |  |  |  | — |  |  |  | (45 | )
Net loss |  | $ | (1,851 | ) |  | $ | (5,813 | ) |  | $ | — |  |  | $ | (7,664 | )

25

Table of Contents
NEXTPLAT CORP AND SUBSIDIARIES
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(Unaudited)

For the Three Months Ended September 30, 2023 |  | e-Commerce Operations |  |  | Healthcare Operations |  |  | Eliminations |  |  | Total |
Pharmacy prescription and other revenue, net of PBM fees |  | $ | — |  |  | $ | 9,888 |  |  | $ | — |  |  | $ | 9,888 |
e-Commerce revenue |  |  | 2,931 |  |  |  | — |  |  |  | — |  |  |  | 2,931 |
Pharmacy 340B contract revenue |  |  | — |  |  |  | 2,471 |  |  |  | — |  |  |  | 2,471 |
Revenues, net |  | $ | 2,931 |  |  | $ | 12,359 |  |  | $ | — |  |  | $ | 15,290 |
Expenses: |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Cost of revenue |  |  | 2,127 |  |  |  | 8,578 |  |  |  | — |  |  |  | 10,705 |
Selling, general and administrative |  |  | 1,978 |  |  |  | 2,269 |  |  |  | (60 | ) |  |  | 4,187 |
Salaries, wages and payroll taxes |  |  | 564 |  |  |  | 1,919 |  |  |  | — |  |  |  | 2,483 |
Professional fees |  |  | 278 |  |  |  | 243 |  |  |  | — |  |  |  | 521 |
Depreciation and amortization |  |  | 164 |  |  |  | 707 |  |  |  | — |  |  |  | 871 |
Total expenses |  |  | 5,111 |  |  |  | 13,716 |  |  |  | (60 | ) |  |  | 18,767 |
Loss before other (income) expense |  |  | (2,180 | ) |  |  | (1,357 | ) |  |  | 60 |  |  |  | (3,477 | )
Other (income) expense |  |  | (76 | ) |  |  | 17 |  |  |  | 60 |  |  |  | 1 |
Loss before income taxes |  |  | (2,104 | ) |  |  | (1,374 | ) |  |  | — |  |  |  | (3,478 | )
Income taxes |  |  | (23 | ) |  |  | — |  |  |  | — |  |  |  | (23 | )
Loss before equity method investment |  |  | (2,127 | ) |  |  | (1,374 | ) |  |  | — |  |  |  | (3,501 | )
Gain on equity method investment |  |  | 6,138 |  |  |  | — |  |  |  | — |  |  |  | 6,138 |
Equity in net loss of affiliate |  |  | — |  |  |  | — |  |  |  | — |  |  |  | — |
Net loss |  | $ | 4,011 |  |  | $ | (1,374 | ) |  | $ | — |  |  | $ | 2,637 |

26

Table of Contents
NEXTPLAT CORP AND SUBSIDIARIES
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(Unaudited)

For the Nine Months Ended September 30, 2024 |  | e-Commerce Operations |  |  | Healthcare Operations |  |  | Eliminations |  |  | Total |
Pharmacy prescription and other revenue, net of PBM fees |  | $ | — |  |  | $ | 30,922 |  |  | $ | — |  |  | $ | 30,922 |
e-Commerce revenue |  |  | 10,210 |  |  |  | — |  |  |  | — |  |  |  | 10,210 |
Pharmacy 340B contract revenue |  |  | — |  |  |  | 8,717 |  |  |  | — |  |  |  | 8,717 |
Revenues, net |  | $ | 10,210 |  |  | $ | 39,639 |  |  | $ | — |  |  | $ | 49,849 |
Expenses: |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Cost of revenue |  |  | 7,217 |  |  |  | 28,496 |  |  |  | — |  |  |  | 35,713 |
Selling, general and administrative |  |  | 3,517 |  |  |  | 3,179 |  |  |  | (180 | ) |  |  | 6,516 |
Salaries, wages and payroll taxes |  |  | 1,744 |  |  |  | 6,540 |  |  |  | — |  |  |  | 8,284 |
Impairment loss |  |  | — |  |  |  | 13,653 |  |  |  | — |  |  |  | 13,653 |
Professional fees |  |  | 2,608 |  |  |  | 1,525 |  |  |  | — |  |  |  | 4,133 |
Depreciation and amortization |  |  | 417 |  |  |  | 1,870 |  |  |  | — |  |  |  | 2,287 |
Total expenses |  |  | 15,503 |  |  |  | 55,263 |  |  |  | (180 | ) |  |  | 70,586 |
Loss before other (income) expense |  |  | (5,293 | ) |  |  | (15,624 | ) |  |  | 180 |  |  |  | (20,737 | )
Other income |  |  | (735 | ) |  |  | (166 | ) |  |  | 180 |  |  |  | (721 | )
Loss before income taxes |  |  | (4,558 | ) |  |  | (15,458 | ) |  |  | — |  |  |  | (20,016 | )
Income taxes |  |  | (92 | ) |  |  | — |  |  |  | — |  |  |  | (92 | )
Net loss |  | $ | (4,650 | ) |  | $ | (15,458 | ) |  | $ | — |  |  | $ | (20,108 | )

27

Table of Contents
NEXTPLAT CORP AND SUBSIDIARIES
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(Unaudited)

For the Nine Months Ended September 30, 2023 |  | e-Commerce Operations |  |  | Healthcare Operations |  |  | Eliminations |  |  | Total |
Pharmacy prescription and other revenue, net of PBM fees |  | $ | — |  |  | $ | 9,888 |  |  | $ | — |  |  | $ | 9,888 |
e-Commerce revenue |  |  | 8,764 |  |  |  | — |  |  |  | — |  |  |  | 8,764 |
Pharmacy 340B contract revenue |  |  | — |  |  |  | 2,471 |  |  |  | — |  |  |  | 2,471 |
Revenues, net |  | $ | 8,764 |  |  | $ | 12,359 |  |  | $ | — |  |  | $ | 21,123 |
Expenses: |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Cost of revenue |  |  | 6,495 |  |  |  | 8,579 |  |  |  | — |  |  |  | 15,074 |
Selling, general and administrative |  |  | 5,287 |  |  |  | 2,269 |  |  |  | (60 | ) |  |  | 7,496 |
Salaries, wages and payroll taxes |  |  | 2,120 |  |  |  | 1,919 |  |  |  | — |  |  |  | 4,039 |
Professional fees |  |  | 1,143 |  |  |  | 242 |  |  |  | — |  |  |  | 1,385 |
Depreciation and amortization |  |  | 493 |  |  |  | 708 |  |  |  | — |  |  |  | 1,201 |
Total expenses |  |  | 15,538 |  |  |  | 13,717 |  |  |  | (60 | ) |  |  | 29,195 |
Loss before other (income) expense |  |  | (6,774 | ) |  |  | (1,358 | ) |  |  | 60 |  |  |  | (8,072 | )
Other (income) expense |  |  | (635 | ) |  |  | 17 |  |  |  | 60 |  |  |  | (558 | )
Loss before income taxes |  |  | (6,139 | ) |  |  | (1,375 | ) |  |  | — |  |  |  | (7,514 | )
Income taxes |  |  | (75 | ) |  |  | — |  |  |  | — |  |  |  | (75 | )
Loss before equity method investment |  |  | (6,214 | ) |  |  | (1,375 | ) |  |  | — |  |  |  | (7,589 | )
Gain on equity method investment |  |  | 6,138 |  |  |  | — |  |  |  | — |  |  |  | 6,138 |
Equity in net loss of affiliate |  |  | (1,440 | ) |  |  | — |  |  |  | — |  |  |  | (1,440 | )
Net loss |  | $ | (1,516 | ) |  | $ | (1,375 | ) |  | $ | — |  |  | $ | (2,891 | )

|  | e-Commerce Operations |  |  | Healthcare Operations |  |  | Eliminations |  |  | Total |
Total assets as of September 30, 2024 |  | $ | 38,566 |  |  | $ | 19,212 |  |  | $ | (16,679 | ) |  | $ | 41,099 |
Total assets as of December 31, 2023 |  | $ | 40,764 |  |  | $ | 40,384 |  |  | $ | (16,679 | ) |  | $ | 64,469 |

28

Table of Contents
NEXTPLAT CORP AND SUBSIDIARIES
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(Unaudited)

Note 19. Concentrations

e-Commerce Operations concentrations:

Customers:

Sales to customers through Amazon accounted for 35.8% and 49.1% of the Company’s revenues during the nine months ended September 30, 2024 and 2023, respectively. No other customer accounted for 10% or more of the Company’s revenues for either period.

Suppliers:

The following table sets forth information as to each supplier that accounted for 10% or more of the Company’s purchases for the three and nine months ended September 30, 2024 and 2023 (in thousands):

|  | For the Three Months Ended September 30, |
|  | 2024 |  |  | 2023 |
|  | Amount |  |  | % of Total Purchases |  |  | Amount |  |  | % of Total Purchases |
Iridium Satellite |  | $ | 378 |  |  |  | 14.5 | % |  | $ | — |  |  |  | — | %
Garmin |  | $ | 373 |  |  |  | 14.3 | % |  | $ | 444 |  |  |  | 23.2 | %
Globalstar |  | $ | 280 |  |  |  | 10.8 | % |  | $ | 186 |  |  |  | 9.7 | %
Maklink |  | $ | 264 |  |  |  | 10.1 | % |  | $ | — |  |  |  | — | %

|  | For the Nine Months Ended September 30, |
|  | 2024 |  |  | 2023 |
|  | Amount |  |  | % of Total Purchases |  |  | Amount |  |  | % of Total Purchases |
Iridium Satellite |  | $ | 1,314 |  |  |  | 18.1 | % |  | $ | 798 |  |  |  | 12.0 | %
Garmin |  | $ | 867 |  |  |  | 12.0 | % |  | $ | 1,494 |  |  |  | 22.5 | %
Globalstar |  | $ | 754 |  |  |  | 10.4 | % |  | $ | 706 |  |  |  | 10.6 | %

29

Table of Contents
NEXTPLAT CORP AND SUBSIDIARIES
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(Unaudited)

Geographic:

The following table sets forth revenue as to each geographic location (in thousands):

|  | For the Three Months Ended September 30, |
|  | 2024 |  |  | 2023 |
|  | Amount |  |  | % of Total |  |  | Amount |  |  | % of Total |
Europe |  | $ | 2,018 |  |  |  | 52.6 | % |  | $ | 1,715 |  |  |  | 58.5 | %
North America |  |  | 1,349 |  |  |  | 35.2 | % |  |  | 737 |  |  |  | 25.1 | %
South America |  |  | 10 |  |  |  | 0.3 | % |  |  | 432 |  |  |  | 14.7 | %
Asia and Pacific |  |  | 429 |  |  |  | 11.2 | % |  |  | 24 |  |  |  | 0.8 | %
Africa |  |  | 28 |  |  |  | 0.7 | % |  |  | 23 |  |  |  | 0.8 | %
|  | $ | 3,834 |  |  |  | 100 | % |  | $ | 2,931 |  |  |  | 100 | %

|  | For the Nine Months Ended September 30, |
|  | 2024 |  |  | 2023 |
|  | Amount |  |  | % of Total |  |  | Amount |  |  | % of Total |
Europe |  | $ | 5,434 |  |  |  | 53.2 | % |  | $ | 5,382 |  |  |  | 61.4 | %
North America |  |  | 2,894 |  |  |  | 28.3 | % |  |  | 2,194 |  |  |  | 25.0 | %
South America |  |  | 41 |  |  |  | 0.4 | % |  |  | 1,026 |  |  |  | 11.7 | %
Asia and Pacific |  |  | 1,275 |  |  |  | 12.5 | % |  |  | 121 |  |  |  | 1.4 | %
Africa |  |  | 566 |  |  |  | 5.5 | % |  |  | 41 |  |  |  | 0.5 | %
|  | $ | 10,210 |  |  |  | 100 | % |  | $ | 8,764 |  |  |  | 100 | %

30

Table of Contents
NEXTPLAT CORP AND SUBSIDIARIES
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(Unaudited)

Healthcare operations concentrations:

Suppliers:

Progressive Care had significant concentrations with one vendor. The purchases from this significant vendor were 98.0% of total vendor purchases for the nine months ended September 30, 2024.

Customers:

Progressive Care trade receivables are primarily from prescription medications billed to various insurance providers. Ultimately, the insured is responsible for payment should the insurance company not reimburse Progressive Care.

Progressive Care derives a significant portion of sales from prescription drug sales reimbursed through prescription drug plans administered by PBM companies. Prescription reimbursements from our three most significant PBMs were as follows:

|  | Nine Months Ended September 30, 2024 |
A |  |  | 29 | %
B |  |  | 25 | %
C |  |  | 11 | %

31

Table of Contents
ITEM 2. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

The following information should be read in conjunction with the Condensed Consolidated Financial Statements and the notes thereto contained elsewhere in this report. Statements made in this Item 2, “Management’s Discussion and Analysis of Financial Condition and Results of Operations,” and elsewhere in this quarterly report on Form 10-Q that do not consist of historical facts, are “forward-looking statements.” Statements accompanied or qualified by, or containing words such as “may,” “will,” “should,” “believes,” “expects,” “intends,” “plans,” “projects,” “estimates,” “predicts,” “potential,” “outlook,” “forecast,” “anticipates,” “presume,” and “assume” constitute forward-looking statements, and as such, are not a guarantee of future performance. The statements involve factors, risks and uncertainties, the impact or occurrence of which can cause actual results to differ materially from the expected results described in such statements. Risks and uncertainties can include, among others, fluctuations in general business cycles and changing economic conditions; changing product demand and industry capacity; increased competition and pricing pressures; advances in technology that can reduce the demand for the Company’s products, as well as other factors, many or all of which may be beyond the Company’s control. Consequently, investors should not place undue reliance upon forward-looking statements as predictive of future results. The Company disclaims any obligation to update the forward-looking statements in this report.

You should consider the risks and difficulties frequently encountered by early-stage companies, particularly those engaged in new and rapidly evolving markets and technologies. Our limited operating history provides only a limited historical basis to assess the impact that critical accounting policies may have on our business and our financial performance.

We encourage you to review our periodic reports filed with the SEC and included in the SEC’s EDGAR database, including our Annual Report on Form 10-K for the year ended December 31, 2023, filed with the SEC on April 11, 2024, and our subsequent public filings with the SEC. We encourage you to review Progressive Care's. periodic reports filed with the SEC and included in the SEC’s EDGAR database, including Progressive Care Annual Report on Form 10-K for the year ended December 31, 2023, filed with the SEC on April 11, 2024, and Progressive Care's subsequent public filings with the SEC.

Overview

e-Commerce Operations:

Leveraging the e-commerce experience of the Company’s management team and the Company’s existing e-commerce platforms, the Company has embarked upon the rollout of a state-of-the-art e-commerce platform to collaborate with businesses to optimize their ability to sell their goods online, domestically, and internationally, and enabling customers and partners to optimize their e-Commerce presence and revenue, which we expect will become the focus of the Company’s business in the future. Historically, the business of NextPlat has been the provision of a comprehensive array of Satellite Industry communication services, and related equipment sales. The Company operates two main e-commerce websites as well as 25 third-party e-Commerce storefronts such as Alibaba, Amazon, and Walmart. These e-Commerce venues form an effective global network serving thousands of consumers, enterprises, and governments. NextPlat has announced its intention to broaden its e-commerce platform and is implementing comprehensive systems upgrades to support this initiative.

e-Commerce transaction volumes at the Company’s owned and operated websites in the UK and Unites States continued to grow throughout the third quarter setting monthly performance records.

32

Table of Contents
ITEM 2. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

Healthcare Operations:

Progressive Care, through its wholly-owned subsidiaries, currently owns and operates five pharmacies, which generate most of its pharmacy revenues, which is derived from dispensing medications to their patients. Progressive Care also provides patient health risk reviews and free same-day delivery.

Progressive Care provides third party administrator (TPA), data management, COVID-19 related diagnostics and vaccinations, prescription pharmaceuticals, compounded medications, telepharmacy services, anti-retroviral medications, medication therapy management, the supply of prescription medications to long-term care facilities, medication adherence packaging, contracted pharmacy services for 340B covered entities under the 340B Drug Discount Pricing Program, and health practice risk management. Progressive Care and its subsidiaries are focused on improving the lives of patients with complex chronic diseases through a patient and provider engagement and their partnerships with payors, pharmaceutical manufacturers, and distributors. Progressive Care offers a broad range of solutions to address the dispensing, delivery, dosing, and reimbursement of clinically intensive, high-cost drugs.

Progressive Care’s pharmacies also provide contracted pharmacy services for 340B covered entities under the 340B Drug Discount Pricing Program. Under the terms of these agreements, Progressive Care’s pharmacies act as a pass-through for reimbursements on prescription claims adjudicated on behalf of the 340B covered entities in exchange for a dispensing fee per prescription. These fees vary by the covered entity and the level of services provided by Progressive Care.

Progressive Care’s focus is on complex chronic diseases that generally require multiyear or lifelong therapy, which drives recurring revenue and sustainable growth. Progressive Care’s pharmacy services revenue growth is from expanding its services, new drugs coming to market, new indications for existing drugs, volume growth with current clients, and additions of new customers due to its focus on higher patient engagement, benefit of free delivery to the patient, and clinical expertise. The pharmacies also expand revenue growth through the signing of new contract pharmacy service and data management contracts with 340B covered entities.

Progressive Care provides data management and TPA services for 340B covered entities, pharmacy analytics, and programs to manage Healthcare Effectiveness Data and Information Set (HEDIS) Quality Measures including Medication Adherence. These offerings cater to the need for frontline providers to understand best practices, patient behaviors, care management processes, and the financial mechanisms behind these decisions. ClearMetrX provides data access, and actionable insights that providers and support organizations can use to improve their practice and patient care. ClearMetrX’s TPA services include management of wholesale accounts, patient eligibility with regard to the 340B drug program, development and review of 340B policies and procedures, and management of receivables.

Acquisition of Progressive Care Inc.

On August 30, 2022, NextPlat entered into a Securities Purchase Agreement (the “SPA”) between NextPlat and Progressive Care, under which NextPlat, its Executive Chairman and Chief Executive Officer, Charles M. Fernandez, board member, Rodney Barreto, and certain other investors invested an aggregate of $8.3 million into Progressive Care. In connection with the SPA, NextPlat purchased 3,000 newly issued Units of Progressive Care valued at $6 million, with each Unit comprised of one share of Progressive Care’s Series B Convertible Preferred Stock, $0.001 par value, and one Investor Warrant to purchase a share of Series B Convertible Preferred Stock at an exercise price of $2,000 The Investor Warrants may also be exercised, in whole or in part, by means of a cashless exercise. The Convertible Preferred Stock has a stated value of $2,000 per share and each Preferred Stock share has the equivalent voting rights of 500 common stock shares (after giving effect to the Reverse Stock Split described below). Each share of Series B Convertible Preferred Stock is convertible at any time at the option of the holder into shares of Progressive Care common stock determined by dividing the stated value by the conversion price which is $4.00 (after giving effect to the Reverse Stock Split described below).

33

Table of Contents
ITEM 2. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

In addition, on August 30, 2022, NextPlat Corp, Messrs. Fernandez and Barreto, and certain other investors (collectively, the “NextPlat Investors”) entered into a Modification Agreement wherein the terms were modified for an existing Secured Convertible Promissory Note (the “Note”) originally held by a third party note holder and sold to the NextPlat Investors. The NextPlat Investors purchased the Note as part of a Confidential Note Purchase and Release Agreement between the former note holder and the NextPlat Investors. As of the date of the SPA, the aggregate amount of principal and interest outstanding on the Note was approximately $2.8 million. As part of the Modification Agreement, various terms of the Note were modified, among them, the Conversion Price for the Note was modified to a fixed price of $4.00 per share of common stock (after giving effect to the Reverse Stock Split described below). In addition, the Note was modified to provide for mandatory conversion upon the later to occur of (a) the completion of the Company’s reverse stock split, and (b) the listing of the Company’s common stock on a national exchange, including the Nasdaq Capital Market, the Nasdaq Global Market, or the New York Stock Exchange. Also, pursuant to the SPA, Messrs. Fernandez and Barreto were nominated for election to Progressive Care’s Board of Directors.

On September 13, 2022, the Progressive Care Board of Directors appointed Charles M. Fernandez as Chairman of the Board of Directors and Rodney Barreto as the Vice Chairman of the Board of Directors.

On November 11, 2022, Progressive Care’s board appointed Mr. Fernandez to serve as the new Chief Executive Officer of Progressive Care.

On December 29, 2022, Progressive Care filed a Certificate of Amendment to Articles of Incorporation (the “Amendment to Articles”) with the Secretary of State of the State of Delaware. Pursuant to the Amendment to Articles, each 200 shares of Progressive Care’s common stock outstanding was converted into one share of common stock (the “Reverse Stock Split”) and the number of shares of common stock that Progressive Care is authorized to issue was reduced to 100 million (the “Reduction in Authorized Stock”). The Reverse Stock Split and the Reduction in Authorized Stock were approved by the Progressive Care's board of directors and shareholders.

On May 5, 2023, NextPlat entered into a Securities Purchase Agreement (the “SPA”) with Progressive Care, pursuant to which NextPlat purchased 455,000 newly issued units of securities from Progressive Care (the “Units”) at a price per Unit of $2.20 for an aggregate purchase price of $1 million (the “Unit Purchase”). Each Unit consisted of one share of common stock, par value $0.0001 per share, of Progressive Care and one warrant to purchase a share of common stock (the “PIPE Warrants”). The PIPE Warrants have a three-year term and are immediately exercisable. Each PIPE Warrant is exercisable at $2.20 per share of common stock. On May 9, 2023, the Companies closed the transactions contemplated in the SPA. Progressive Care received cash proceeds of $880,000, net of placement agent commission of $70,000 and legal fees of $50,000.

Simultaneous with the closing, Progressive Care entered into a Debt Conversion Agreement (the “DCA”) with NextPlat and the other holders (the “Holders”) of that certain Amended and Restated Secured Convertible Promissory Note, dated as of September 2, 2022, made by the Company in the original face amount of approximately $2.8 million (the “Note”). Pursuant to the DCA, NextPlat and the other Holders agreed to convert the total approximately $2.9 million of outstanding principal and accrued and unpaid interest to Progressive Care common Stock at a conversion price of $2.20 per share (the “Debt Conversion”). Of the total 1,312,379 shares of Progressive Care common stock issued upon conversion of the Note pursuant to the DCA, NextPlat received 570,599 shares, Charles M. Fernandez, the Company’s Chairman and Chief Executive Officer, received 228,240 shares, and Rodney Barreto, the Company’s Vice-Chairman of the Board of Directors, received 228,240 shares. In addition, each of the Holders also received a warrant to purchase one share of Progressive Care common stock for each share of Progressive Care common stock they received upon conversion of the Note (the “Conversion Warrants”). The Conversion Warrants have a three-year term and are immediately exercisable. Each Conversion Warrant is exercisable at $2.20 per share of Common Stock. In addition, the Company issued 330,000 warrants to certain existing Progressive Care investors to induce them to approve the transaction contemplated by the SPA (the “Inducement Warrants”). Charles M. Fernandez and Rodney Barreto received Inducement Warrants to purchase 190,000 and 30,000 shares of Common Stock, respectively. The Inducement Warrants have a three-year term and are immediately exercisable. Each Inducement Warrant is exercisable at $2.20 per share of Common Stock.

34

Table of Contents
ITEM 2. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

On July 1, 2023, NextPlat, along with Messrs. Fernandez and Barreto, exercised common stock purchase warrants and were issued shares of Progressive Care common stock. NextPlat exercised common stock purchase warrants on a cashless basis and was issued 402,269 shares of Progressive Care common stock. NextPlat also exercised common stock purchase warrants on a cash basis and paid consideration in the amount of $506,000 and was issued 230,000 shares of Progressive Care common stock. Mr. Fernandez exercised common stock purchase warrants on a cashless basis and was issued 211,470 shares of Progressive Care common stock. Mr. Barreto exercised common stock purchase warrants on a cashless basis and was issued 130,571 shares of Progressive Care common stock. At the time of exercise, all of the above common stock purchase warrants were in-the-money. After the exercise of the common stock purchase warrants, NextPlat, Messrs. Fernandez and Barreto collectively owned approximately 53% of Progressive Care’s voting stock.

Also, on July 1, 2023, NextPlat, along with Messrs. Fernandez and Barreto, entered into a voting agreement whereby at any annual or special shareholders meeting of Progressive Care’s stockholders, and whenever the holders of Progressive Care’s common stock act by written consent, Messrs. Fernandez and Barreto agreed to vote all of their shares of Progressive Care common stock (including any new shares acquired after the date of the voting agreement or acquired through the conversion of securities convertible into Progressive Care common stock) that they own, directly or indirectly, in the same manner that NextPlat votes its Progressive Care common stock and equivalents. The voting agreement is irrevocable and perpetual in term.

As a result of the common stock purchase warrant exercises and the entry into the voting agreement, NextPlat concluded that there was a change in control in Progressive Care. As of July 1, 2023, NextPlat has the right to control more than 50 percent of the voting stock of Progressive Care through the concurrent common stock purchase warrant exercises and voting agreement noted above. Beginning on July 1, 2023, the Company changed the accounting method for its investment in Progressive Care, which prior to July 1, 2023 had been accounted for as an equity method investment to consolidation under the voting interest model in FASB ASC Topic 805. Therefore, Progressive Care became a consolidated subsidiary of the Company on July 1, 2023.

On April 12, 2024, NextPlat entered into a Merger Agreement and Plan of Reorganization (the “Merger Agreement”) with Progressive Care Inc, and Progressive Care LLC, a Nevada limited liability company and a direct, wholly owned subsidiary of NextPlat (“Merger Sub”). Pursuant to the terms of the Merger Agreement, upon the approval of NextPlat's and Progressive Care's shareholders, Progressive Care would merge with and into Merger Sub (the “Merger”), with Merger Sub being the surviving entity of the Merger. The result of which being that Progressive Care would become a wholly-owned subsidiary of NextPlat.

On September 13, 2024, the shareholders of each of NextPlat and Progressive Care approved the Merger Agreement and the transactions contemplated thereby.

On October 1, 2024, at 12:01 Eastern time, the Merger became effective and Progressive Care merged with and into Mergers Sub and thereby became a wholly owned subsidiary of NextPlat. In connection with the Merger, each share of Progressive Care common stock that was issued and outstanding immediately prior to the effective time of the Merger was converted into 1.4865 shares of NextPlat common stock, and each warrant to purchase Progressive Care common stock that was outstanding and unexercised immediately prior to the effective time of the Merger automatically converted into a warrant to purchase shares of NextPlat common stock with each such warrant having and being subject to the same terms and conditions (including vesting and exercisability terms) as were applicable to such Progressive Care warrant immediately before the effective time.

Business acquisition of Outfitter Satellite, Inc.

On March 25, 2024, the Company entered into a Stock Purchase Agreement with James T. McKinley, pursuant to which the Company agreed to purchase all of the issued and outstanding shares of common stock of Out fitter Satellite, Inc. (“Outfitter”). The closing of the transaction occurred on April 1, 2024.

Outfitter provides consumers, commercial and government customers, with advanced satellite-based connectivity solutions from leading brands, including Iridium, Inmarsat and Globalstar.

35

Table of Contents
ITEM 2. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

Critical Accounting Policies and Estimates

The significant accounting policies of the Company were described in Note 1. to the Audited Consolidated Financial Statements included in the Company’s Form 10-K for the fiscal year ended December 31, 2023. There have been no material changes to our critical accounting policies and estimates from the information provided in Item 7. Management’s Discussion and Analysis of Financial Condition and Results of Operations included in our 2023 Form 10-K. The most recently adopted accounting pronouncements and accounting pronouncements to be adopted by the Company are described in Note 3 in the Notes to our Unaudited Condensed Consolidated Financial Statements included in this Quarterly Report on Form 10-Q.

Results of Operations for the three months ended September 30, 2024 compared to the three months ended September 30, 2023 (in thousands):

|  | Three Months Ended September 30, |  |
|  | 2024 |  |  | 2023 |  |  | $ Change |  |  | % Change |
Revenue, net |  | $ | 15,367 |  |  | $ | 15,290 |  |  | $ | 77 |  |  |  | 1 | %
Cost of revenue |  |  | 11,847 |  |  |  | 10,705 |  |  |  | 1,142 |  |  |  | 11 | %
Gross profit |  |  | 3,520 |  |  |  | 4,585 |  |  |  | (1,065 | ) |  |  | (23 | )%
Operating expenses |  |  | 11,519 |  |  |  | 8,062 |  |  |  | 3,457 |  |  |  | 43 | %
Loss before other (income) expense |  |  | (7,999 | ) |  |  | (3,477 | ) |  |  | (4,522 | ) |  |  | 130 | %
Other (income) expense |  |  | (380 | ) |  |  | 1 |  |  |  | (381 | ) |  |  | nm |
Loss before income taxes |  |  | (7,619 | ) |  |  | (3,478 | ) |  |  | (4,141 | ) |  |  | 119 | %
Income taxes |  |  | (45 | ) |  |  | (23 | ) |  |  | (22 | ) |  |  | 96 | %
Loss before equity method investment |  |  | (7,664 | ) |  |  | (3,501 | ) |  |  | (4,163 | ) |  |  | 119 | %
Gain on remeasurement of fair value of equity interest in affiliate prior to acquisition |  |  | — |  |  |  | 6,138 |  |  |  | (6,138 | ) |  |  | (100 | )%
Net (loss) income |  |  | (7,664 | ) |  |  | 2,637 |  |  |  | (10,301 | ) |  |  | (391 | )%
Net loss attributable to non-controlling interest |  |  | 3,448 |  |  |  | 811 |  |  |  | 2,637 |  |  |  | 325 | %
Net (loss) income attributable to NextPlat Corp. |  | $ | (4,216 | ) |  | $ | 3,448 |  |  | $ | (7,664 | ) |  |  | (222 | )%

nm = not meaningful

For the three months ended September 30, 2024 and 2023, we recognized overall revenue from operations of approximately $15.4 million and $15.3 million, respectively, an overall increase of approximately $0.1 million for the three months ended September 30, 2024, when compared to the three months ended September 30, 2023. The increase in revenue was primarily attributable to an increase of approximately $0.9 million from e-Commerce Operations, offset by a decrease of approximately $0.8 million from Healthcare Operations.

Gross profit margins decreased from approximately 30.0% for the three months ended September 30, 2023, to 22.9% for the three months ended September 30, 2024. The decrease in gross profit margins during the third quarter of 2024 compared to the same period in 2023, was primarily attributable to the decrease in reimbursement rates experienced in Healthcare Operations. The gross profit margins remained consistent for e-Commerce Operations for the third quarter of 2024 compared to the same period in 2023

Loss before other (income) expense increased by approximately $4.5 million for the three months ended September 30, 2024, when compared to the three months ended September 30, 2023, as a result of the increase in operating expenses of approximately $3.5 million and the decrease in gross profit of approximately $1.1 million See detailed discussion below. The increase in operating expenses included non-recurring expenses and losses that are not indicative of our regular operations, including impairment losses of approximately $3.7 million and approximately $1.4 million of non-recurring operating expenses associated with our merger with Progressive Care. Without those non-recurring items, loss before other (income) expense would have been approximately $2.9 million for the three months ended September 30, 2024 compared to $3.5 million for the three months ended September 30, 2023.

36

Table of Contents
ITEM 2. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

Revenue

Our revenues were as follows (in thousands):

|  | Three Months Ended September 30, |  |  |  |  |  |  |  |
|  | 2024 |  |  | 2023 |  |  |  |  |  |  |  |  |
|  | Dollars |  |  | % of Revenue |  |  | Dollars |  |  | % of Revenue |  |  | $ Change |  |  | % Change |
Sales of products, net: |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
e-Commerce revenue |  | $ | 3,834 |  |  |  | 25 | % |  | $ | 2,931 |  |  |  | 19 | % |  | $ | 903 |  |  |  | 31 | %
Pharmacy prescription and other revenue, net of PBM fees |  |  | 9,076 |  |  |  | 59 | % |  |  | 9,888 |  |  |  | 65 | % |  |  | (812 | ) |  |  | (8 | )%
Sub total |  |  | 12,910 |  |  |  | 84 | % |  |  | 12,819 |  |  |  | 84 | % |  |  | 91 |  |  |  | 1 | %
Revenues from services: |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Pharmacy 340B contract revenue |  |  | 2,457 |  |  |  | 16 | % |  |  | 2,471 |  |  |  | 16 | % |  |  | (14 | ) |  |  | (1 | )%
Revenues, net |  | $ | 15,367 |  |  |  | 100 | % |  | $ | 15,290 |  |  |  | 100 | % |  | $ | 77 |  |  |  | 1 | %

Revenue, net for the three months ended September 30, 2024, consisted of e-Commerce sales of satellite phones, tracking devices, accessories, and airtime plans, pharmacy prescription revenues, and 340B contract revenues. For the three months ended September 30, 2024, overall revenues were approximately $15.4 million compared to $15.3 million for the three months ended September 30, 2023, an increase in of approximately $0.1 million or 0.5%.

Total e-Commerce revenues were approximately $3.8 million and $2.9 million for the three months ended September 30, 2024 and 2023, respectively, an increase of approximately $0.9 million mainly due to the Outfitter acquisition on April 1, 2024.

Total pharmacy prescription and 340B contract revenues were approximately $11.5 million and $12.4 million for the three months ended September 30, 2024 and 2023, respectively, a decrease of approximately $0.8 million. The decrease was primarily due to a decrease in pharmacy prescription reimbursement rates. The pharmacy filled approximately 128,000 and 122,000 prescriptions for the three months ended September 30, 2024 and 2023, respectively.

37

Table of Contents
ITEM 2. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

Operating Expenses

Our operating expenses were as follows (in thousands):

|  | Three Months Ended September 30, |  |  |
|  | 2024 |  |  | 2023 |  |  | $ Change |  |  | % Change |
Selling, general and administrative |  | $ | 2,293 |  |  | $ | 4,187 |  |  | $ | (1,894 | ) |  |  | (45 | )%
Salaries, wages and payroll taxes |  |  | 2,875 |  |  |  | 2,483 |  |  |  | 392 |  |  |  | 16 | %
Impairment loss |  |  | 3,729 |  |  |  | — |  |  |  | 3,729 |  |  |  | 100 | %
Professional fees |  |  | 2,144 |  |  |  | 521 |  |  |  | 1,623 |  |  |  | 312 | %
Depreciation and amortization |  |  | 478 |  |  |  | 871 |  |  |  | (393 | ) |  |  | (45 | )%
Operating expenses |  | $ | 11,519 |  |  | $ | 8,062 |  |  | $ | 3,457 |  |  |  | 43 | %

Total operating expenses for the three months ended September 30, 2024, were approximately $11.5 million, an increase of approximately $3.5 million, or 42.9%, from total operating expenses for the three months ended September 30, 2023, of approximately $8.1 million. Factors contributing to the increase are described below.

Selling, general and administrative expenses were approximately $2.3 million and $4.2 million for the three months ended September 30, 2024 and 2023, respectively, a decrease of approximately $1.9 million or 45.2%. The decrease for the three months ended September 30, 2024, was mainly attributable to the decrease in stock-based compensation of approximately $2.1 million, partially offset by an increase in operating expenses of approximately $0.1 million related to the Outfitter acquisition on April 1, 2024, and an increase of approximately $0.1 million related to an allowance for credit losses on the note receivable from related party for the Next Borough Capital Fund, LP unsecured promissory note.

Salaries, wages and payroll taxes were approximately $2.9 million and $2.5 million for the three months ended September 30, 2024 and 2023, respectively, an increase of approximately $0.4 million or 15.8%. The increase was mainly attributable to an increased headcount in our Healthcare Operations of approximately $0.3 million and approximately $0.1 million related to the Outfitter acquisition on April 1, 2024.

38

Table of Contents
ITEM 2. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

The Company performed a long-lived assets impairment test as it relates to the Healthcare Operations reporting segment during the three months ended September 30, 2024 and it was determined that the carrying amount of the asset group at September 30, 2024 exceeded its fair value resulting in the Company recording a non-cash impairment charge to certain long-lived assets, primarily intangible assets, of approximately $3.7 million during the period. Refer to Note 11. Goodwill and Intangible Assets to our quarterly financials for additional details on the impairment charge, valuation methodologies, inputs used in the fair value measurements, and the changes in intangible assets for the period.

Professional fees were approximately $2.1 million and $0.5 million for the three months ended September 30, 2024 and 2023, respectively, an increase of approximately $1.6 million or 311.5%. The increase was mainly attributable to the settlement of litigation and associated legal fees with the e-Commerce Operations of approximately $1.0 million, legal and consulting fees as it relates to the merger of Progressive Care of approximately $0.4 million, and fees associated with the shareholders meetings held during September 2024 of approximately $0.2 million. Management does not expect these increases in professional fees to be recurring expenses in the foreseeable future and are not indicative of projected full year results.

Depreciation and amortization expenses were approximately $0.5 million and $0.9 million for the three months ended September 30, 2024 and 2023, respectively, a decrease of approximately $0.4 million or 45.1%. The decrease was attributable to the decrease in intangible assets amortization related to Healthcare Operations of approximately $0.4 million.

Total Other Income

Our total other income increased by approximately $0.4 million for the three months ended September 30, 2024 when compared to same period in 2023.The increase consisted of gain on disposal of property and equipment of approximately $0.1 million and a favorable change in foreign currency rates approximately $0.3 million.

Equity Method Investment

For the three months ended September 30, 2023, we recorded a gain on the remeasurement of fair value of equity method investment of our affiliate, Progressive Care, of approximately $6.1 million which was accounted for as an equity method investment. Effective July 1, 2023, Progressive Care became a consolidated subsidiary of the Company, which resulted in a change in the accounting treatment from equity method to consolidation.

Net (Loss) Income

We recorded net (loss) income of approximately ($7.7 million) and $2.6 million for the three months ended September 30, 2024 and 2023, respectively. The change was a result of the factors described above.

Comprehensive (Loss) Income

We recorded comprehensive (loss) income for foreign currency translation adjustments of approximately ($6,000) and $19,000 for the three months ended September 30, 2024 and 2023, respectively. The change was primarily attributed to exchange rate variances.

39

Table of Contents
ITEM 2. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

Results of Operations for the nine months ended September 30, 2024 compared to the nine months ended September 30, 2023 (in thousands):

|  | Nine Months Ended September 30, |  |  |  |  |  |  |  |  |
|  | 2024 |  |  | 2023 |  |  | $ Change |  |  | % Change |
Revenue, net |  | $ | 49,849 |  |  | $ | 21,123 |  |  | $ | 28,726 |  |  |  | 136 | %
Cost of revenue |  |  | 35,713 |  |  |  | 15,074 |  |  |  | 20,639 |  |  |  | 137 | %
Gross profit |  |  | 14,136 |  |  |  | 6,049 |  |  |  | 8,087 |  |  |  | 134 | %
Operating expenses |  |  | 34,873 |  |  |  | 14,121 |  |  |  | 20,752 |  |  |  | 147 | %
Loss before other income |  |  | (20,737 | ) |  |  | (8,072 | ) |  |  | (12,665 | ) |  |  | 157 | %
Other income |  |  | (721 | ) |  |  | (558 | ) |  |  | (163 | ) |  |  | 29 | %
Loss before income taxes |  |  | (20,016 | ) |  |  | (7,514 | ) |  |  | (12,502 | ) |  |  | 166 | %
Income taxes |  |  | (92 | ) |  |  | (75 | ) |  |  | (17 | ) |  |  | 23 | %
Loss before equity method investment |  |  | (20,108 | ) |  |  | (7,589 | ) |  |  | (12,519 | ) |  |  | 165 | %
Gain on remeasurement of fair value of equity interest in affiliate prior to acquisition |  |  | — |  |  |  | 6,138 |  |  |  | (6,138 | ) |  |  | (100 | )%
Equity in net loss of affiliate |  |  | — |  |  |  | (1,440 | ) |  |  | 1,440 |  |  |  | (100 | )%
Net loss |  |  | (20,108 | ) |  |  | (2,891 | ) |  |  | (17,217 | ) |  |  | 596 | %
Net loss attributable to noncontrolling interest |  |  | 9,100 |  |  |  | 811 |  |  |  | 8,289 |  |  |  | nm |
Net loss attributable to NextPlat Corp. |  | $ | (11,008 | ) |  | $ | (2,080 | ) |  | $ | (8,928 | ) |  |  | 429 | %

nm = not meaningful

For the nine months ended September 30, 2024 and 2023, we recognized overall revenue from operations of approximately $49.8 million and $21.1 million, respectively, an overall increase of approximately $28.7 million for the nine months ended September 30, 2024, when compared to the nine months ended September 30, 2023. The increase in revenue was primarily attributable to an increase of approximately $27.3 million from the Healthcare Operations reportable segment as a result of the Progressive Care acquisition on July 1, 2023, and approximately $1.5 million as it relates to the e-Commerce Operations reportable segment.

Gross profit margins remained fairly consistent at approximately 28% for both the nine months ended September 30, 2024 and 2023. Healthcare Operations continues to experience pressures from medication price increases despite reimbursement rates not keeping pace with those increases.

Our loss before other income increased by approximately $12.7 million for the nine months ended September 30, 2024, when compared to the nine months ended September 30, 2023, as a result of the increase in operating expenses of approximately $20.8 million, offset by the increase in gross profit of approximately $8.1 million. The increase in operating expenses included non-recurring expenses and losses that are not indicative of our regular operations, including impairment losses of approximately $13.7 million and approximately $3.4 million of non-recurring operating expenses associated with our merger with Progressive Care. Without those non-recurring items, loss before other income would have been approximately $3.6 million for the nine months ended September 30, 2024 compared to $8.1 million for the nine months ended September 30, 2023.

40

Table of Contents
ITEM 2. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

Revenue

Our revenues were as follows (in thousands):

|  | Nine Months Ended September 30, |  |  |  |  |  |  |  |  |
|  | 2024 |  |  | 2023 |  |  |  |  |  |  |  |  |
|  | Dollars |  |  | % of Revenue |  |  | Dollars |  |  | % of Revenue |  |  | $ Change |  |  | % Change |
Sales of products, net: |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
e-Commerce revenue |  | $ | 10,210 |  |  |  | 20 | % |  | $ | 8,764 |  |  |  | 41 | % |  |  | 1,446 |  |  |  | 16 | %
Pharmacy prescription and other revenue, net of PBM fees |  |  | 30,922 |  |  |  | 62 | % |  |  | 9,888 |  |  |  | 47 | % |  | $ | 21,034 |  |  |  | 213 | %
Sub total |  |  | 41,132 |  |  |  | 83 | % |  |  | 18,652 |  |  |  | 88 | % |  |  | 22,480 |  |  |  | 121 | %
Revenues from services: |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Pharmacy 340B contract revenue |  |  | 8,717 |  |  |  | 17 | % |  |  | 2,471 |  |  |  | 12 | % |  |  | 6,246 |  |  |  | 253 | %
Revenues, net |  | $ | 49,849 |  |  |  | 100 | % |  | $ | 21,123 |  |  |  | 100 | % |  |  | 28,726 |  |  |  | 136 | %

Revenues, net for the nine months ended September 30, 2024, consisted of e-Commerce sales of satellite phones, tracking devices, accessories, and airtime plans, pharmacy prescription revenue, and 340B contract revenues. For the nine months ended September 30, 2024, overall revenues were approximately $49.8 million compared to $21.1 million for the nine months ended September 30, 2023, an increase in of approximately $28.7 million or 136.0%.

Total e-Commerce revenues were approximately $10.2 million and $8.8 million for the nine months ended September 30, 2024 and 2023, respectively, an increase of approximately $1.4 million mainly due to the Outfitter acquisition on April 1, 2024.

Total pharmacy prescription and 340B contract revenues were approximately $39.6 million and 12.4 million for the nine months ended September 30, 2024 and 2023, respectively. The increase is due to nine months results for Progressive Care included in the 2024 period versus three months results during the same period in 2023. Progressive Care acquisition occurred on July 1, 2023. The pharmacy filled approximately 395,000 prescriptions for the nine months ended September 30, 2024.

41

Table of Contents
ITEM 2. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

Operating Expenses

Our operating expenses were as follows (in thousands):

|  | Nine Months Ended September 30, |  |  |  |  |  |  |  |  |
|  | 2024 |  |  | 2023 |  |  | $ Change |  |  | % Change |
Selling, general and administrative |  | $ | 6,516 |  |  | $ | 7,496 |  |  | $ | (980 | ) |  |  | (13 | )%
Salaries, wages and payroll taxes |  |  | 8,284 |  |  |  | 4,039 |  |  |  | 4,245 |  |  |  | 105 | %
Impairment loss |  |  | 13,653 |  |  |  | — |  |  |  | 13,653 |  |  |  | nm |
Professional fees |  |  | 4,133 |  |  |  | 1,385 |  |  |  | 2,748 |  |  |  | 198 | %
Depreciation and amortization |  |  | 2,287 |  |  |  | 1,201 |  |  |  | 1,086 |  |  |  | 90 | %
Operating expenses |  | $ | 34,873 |  |  | $ | 14,121 |  |  | $ | 20,752 |  |  |  | 147 | %

nm = not meaningful

Total operating expenses for the nine months ended September 30, 2024, were approximately $34.9 million, an increase of approximately $20.8 million or 147.0%, from total operating expenses for the nine months ended September 30, 2023, of approximately $14.1 million. Factors contributing to the increase are described below.

Selling, general and administrative expenses were approximately $6.5 million and $7.5 million for the nine months ended September 30, 2024 and 2023, respectively, a decrease of approximately $1.0 million or 13.1%. The decrease for the nine months ended September 30, 2024, was mainly attributable to a decrease in stock-based compensation of approximately $3.0 million, offset by an increase of approximately $1.7 million relating to operating expenses of the Healthcare Operations as a result of the Progressive Care acquisition on July 1, 2023, approximately $0.2 million relating to the Outfitter acquisition on April 1, 2024, and an increase of approximately $0.1 million relating to the allowance for credit losses on the note receivable from related party for the Next Borough Capital Fund, LP unsecured promissory note.

Salaries, wages and payroll taxes were approximately $8.3 million and $4.0 million for the nine months ended September 30, 2024 and 2023, respectively, an increase of approximately $4.2 million or 105.1%. The increase was mainly attributable to the Healthcare Operations as a result of the Progressive Care acquisition as of July 1, 2023, of approximately $4.0 million, and approximately $0.2 million as it relates to the Outfitter acquisition on April 1, 2024.

The Company performed a goodwill impairment test during the nine months ended September 30, 2024 and it was determined that the carrying amount of goodwill exceeded its fair value resulting in the Company recording a non-cash impairment charge of approximately $0.7 million, recorded to the Healthcare Operations reporting segment. As of September 30, 2024, there was no remaining goodwill as it relates to the Healthcare Operations reporting segment. Refer to Note 11. Goodwill and Intangible Assets for additional details on the impairment charges, valuation methodologies, and inputs used in the fair value measurements.

42

Table of Contents
ITEM 2. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

The Company performed a long-lived assets impairment test as it relates to the Healthcare Operations reporting segment during the nine months ended September 30, 2024 and it was determined that the carrying amount of the asset group exceeded its fair value resulting in the Company recording a non-cash impairment charge to certain long-lived assets, primarily intangible assets, of approximately $12.8 million in total through the end of the third quarter in 2024. Refer to Note 11. Goodwill and Intangible Assets to our quarterly financials for additional details on the impairment charges, valuation methodologies, inputs used in the fair value measurements, and the changes in intangible assets for the period.

The Company recorded approximately $0.1 million of impairment loss related to the write-down of a right-of-use asset as a result of taking the leased equipment out of service and not returning to service in the future. This was recorded to the Healthcare Operations reporting segment for the nine months ended September 30, 2024.

Professional fees were approximately $4.1 million and $1.4 million for the nine months ended September 30, 2024 and 2023, respectively, an increase of approximately $2.7 million or 198.4%. The increase was mainly attributable to the settlement of litigation and associated legal fees with the e-Commerce Operations of approximately $1.1 million, legal and consulting fees as it relates to the merger of Progressive Care, of approximately $1.4 million, and fees associated with the shareholders meetings held during September 2024 of approximately $0.2 million. Management does not expect these increases in professional fees to be recurring expenses in the foreseeable future and are not indicative of projected full year results.

Depreciation and amortization expenses were approximately $2.3 million and $1.2 million for the nine months ended September 30, 2024 and 2023, respectively, an increase of approximately $1.1 million or 90.4%. The increase was attributable to nine months of depreciation and amortization as it relates to the Healthcare Operations reportable segment of approximately $1.1 million compared to three months of depreciation and amortization in the prior year period related to the Healthcare Operations reportable segment from the Progressive Care acquisition on July 1, 2023.

Total Other Income

Our total other income increased by approximately $0.2 million for the nine months ended September 30, 2024 when compared to the same period in 2023, and was mainly due to interest received of approximately $0.2 million, a favorable change in foreign currency rates approximately $0.2 million, and gain on disposal of property and equipment of approximately $0.1 million, which was offset by the non-recurring write off of aged payables of approximately $0.3 million in the prior year period, and Progressive Care management fee of approximately $0.1 million which was eliminated in consolidation during 2024 as a result of Progressive Care acquisition on July 1, 2023.

Equity Method Investment

For the nine months ended September 30, 2023, we recorded a net loss in the equity of our affiliate, Progressive Care, of approximately $1.4 million, and a gain on the remeasurement of fair value of equity method investment of our affiliate, Progressive Care, of approximately $6.1 million, which was accounted for as an equity method investment. Effective July 1, 2023, Progressive Care became a consolidated subsidiary of the Company, which resulted in a change in the accounting treatment from equity method to consolidation.

43

Table of Contents
ITEM 2. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

Net Loss

We recorded net losses of approximately $20.1 million and $2.9 million for the nine months ended September 30, 2024 and 2023, respectively. The change was a result of the factors described above.

Comprehensive Loss

We recorded comprehensive losses for foreign currency translation adjustments of approximately $30,000 and $16,000 for the nine months ended September 30, 2024 and 2023, respectively. The change was primarily attributed to exchange rate variances.

Liquidity and Capital Resources

Liquidity is the ability of a company to generate funds to support its current and future operations, satisfy its obligations, and otherwise operate on an ongoing basis. As of September 30, 2024, we had a cash balance of approximately $20.4 million. Our working capital was approximately $26.1 million at September 30, 2024.

As of the date of this report, the Company’s existing cash resources and existing borrowing availability are sufficient to support planned operations for the next 12 months. As a result, management believes that the existing financial resources are sufficient to continue operating activities for at least one year past the issuance date of the financial statements.

The following table summarizes our cash flows (in thousands):

|  | For the Nine Months Ended September 30, |
|  | 2024 |  |  | 2023 |
Net change in cash from: |  |  |  |  |  |  |  |
Operating activities |  | $ | (4,988 | ) |  | $ | (4,247 | )
Investing activities |  |  | (981 | ) |  |  | 5,388 |
Financing activities |  |  | 50 |  |  |  | 6,330 |
Effect of exchange rate on cash |  |  | (28 | ) |  |  | (16 | )
Change in cash |  |  | (5,947 | ) |  |  | 7,455 |
Cash at end of period |  | $ | 20,360 |  |  | $ | 26,346 |

44

Table of Contents
ITEM 2. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

Cash Flow from Operating Activities

Net cash flows used by operating activities totaled approximately $5.0 million and $4.3 million for the nine months ended September 30, 2024 and 2023, respectively, and changed by approximately $0.7 million period over period. The unfavorable change of approximately $0.7 million was primarily attributable to the following when compared period over period:

● an increase in cash received from e-Commerce Operations of approximately $1.6 million due to year-over-year sales increase; an increase in cash received from Healthcare Operations of approximately $34.0 million was mainly due to nine months results for Progressive Care included in the 2024 period versus three months results during the same period in 2023 as a result of the acquisition of as of July 1, 2023;

● an increase in cash received from interest income and other sources of approximately $0.3 million and represents nine months of interest income on money market accounts in 2024 versus five months in 2023;

● an increase in cash paid for inventory purchases and other costs of revenue if approximately $23.8 million due is mainly due to nine months results for Progressive Care included in the 2024 period versus three months results during the same period in 2023 as a result of the acquisition of as of July 1, 2023, Outfitter acquisition as of April 1, 2024 and increase in inventory purchases for e-Commerce Operations as a result of increased sales;

● an increase in cash paid for salaries and related expenses of approximately $4.2 million, and other recurring operation expenses of approximately $5.1 million, and mainly due to nine months results for Progressive Care included in the 2024 period versus three months results during the same period in 2023 as a result of the acquisition of as of July 1, 2023, and Outfitter acquisition as of April 1, 2024;

● an increase in cash paid for income taxes of approximately $0.1 million;

● an increase in cash paid for merger costs and other non-recurring expense of approximately $3.4 million.

Cash Flow from Investing Activities

Net cash flows (used) provided in investing activities were approximately ($1.0 million) and $5.4 million for the nine months ended September 30, 2024 and 2023, respectively. The cash outflow in 2024 was attributable to the acquisition of Outfitter, compared to the cash inflow in 2023 due to the additional investment in Progressive Care.

Cash Flow from Financing Activities

Cash provided by financing activities were approximately $50,000 for the nine months ended September 30, 2024 primarily attributable to the exercise of warrants and capital contributions of non-controlling interest, offset by repayment of notes payable. Cash provided by financing activities of approximately $6.3 million for the nine months ended September 30, 2023 primarily attributable to the proceeds from a capital raise and exercise of warrants, offset by repayment of notes payable.

45

Table of Contents

Off-Balance Sheet Arrangements

We do not currently have any off-balance sheet arrangements that have or are reasonably likely to have a current or future effect on our financial condition, changes in financial condition, revenues or expenses, results of operations, liquidity, capital expenditures or capital resources that are material to our stockholders.

Our Company has not entered into any transaction, agreement or other contractual arrangement with an entity unconsolidated with us under which we have:

● | an obligation under a guaranteed contract, although we do have obligations under certain sales arrangements including purchase obligations to vendors
● | a retained or contingent interest in assets transferred to the unconsolidated entity or similar arrangement that serves as credit, liquidity or market risk support to such entity for such assets,
● | any obligation, including a contingent obligation, under a contract that would be accounted for as a derivative instrument, or
● | any obligation, including a contingent obligation, arising out of a variable interest in an unconsolidated entity that is held by us and material to us where such entity provides financing, liquidity, market risk or credit risk support to, or engages in leasing, hedging or research and development services with us.

ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK

As a smaller reporting company, as defined in Rule 12b-2 of the Securities Exchange Act of 1934, as amended, we are not required to provide the information required by this Item.

ITEM 4. CONTROLS AND PROCEDURES

(a) Evaluation of disclosure controls and procedures. In accordance with Rule 13a-15(b) under the Securities Exchange Act of 1934, as amended (“Exchange Act”) we carried out an evaluation, under the supervision and with the participation of our management, including our Chief Executive Officer (“CEO”) and Chief Financial Officer (“CFO”), of the effectiveness and design of our disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) of the Exchange Act), as of the end of the period covered by this report. Based on such evaluation, our CEO and CFO have concluded that as of September 30, 2024, our disclosure controls and procedures were effective to provide reasonable assurance that information required to be disclosed by us in reports that we file or submit under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in SEC rules and forms, and is accumulated and communicated to our management, including our CEO and CFO, as appropriate to allow timely decisions regarding required disclosure.

(b) Inherent Limitations on Controls. Management, including the CEO and CFO, does not expect that our disclosure controls and procedures will prevent or detect all errors and fraud. Any control system, no matter how well designed and operated, is based upon certain assumptions and can provide only reasonable, not absolute, assurance that its objectives will be met. Further, no evaluation of controls can provide absolute assurance that misstatements due to error or fraud will not occur or that all control issues and instances of fraud, if any, within the Company have been detected. The design of a control system must reflect the fact that there are resource constraints, and the benefits of controls must be considered relative to their costs.

(c) Changes in internal controls over financial reporting. There has been no change in our internal control over financial reporting during our fiscal quarter ended September 30, 2024, that has materially affected, or is reasonably likely to materially affect, our internal controls over financial reporting.

46

Table of Contents

PART II. OTHER INFORMATION

ITEM 1. LEGAL PROCEEDINGS

On October 15, 2024, the Company settled its ongoing lawsuit with Mr. Thomas Seifert, the Company’s former Chief Financial Officer. Under the terms of the settlement, the Company agreed to pay to Mr. Seifert $150,000 and to reimburse him for legal costs in the amount of $600,000. In exchange, the Company and Mr. Seifert each agreed to dismiss the lawsuit with prejudice and to release the other party from all claims.

On June 17, 2024, Progressive Care was notified of a potential claim that a former employee allegedly suffered a loss due to an alleged breach by Progressive Care of an employment contract with the former employee. Management believes, based on discussions with its legal counsel, that Progressive Care has meritorious defenses against the former employe’s claim. Since receipt of the notice of claim, Progressive Care filed a petition for arbitration against the former employee, asserting that it was the employee who breached the employment contract. Progressive Care will prosecute its claims and will defend any counterclaims vigorously as Progressive Care believes it will prevail on the merits. At this time, we cannot reasonably estimate the amount of the loss.

From time to time, the Company may become involved in litigation relating to claims arising out of our operations in the normal course of business. The Company is not currently involved in any pending legal proceeding or litigation, and, to the best of our knowledge, no governmental authority is contemplating any proceeding to which the Company is a party or to which any of the Company’s properties is subject, which would reasonably be likely to have a material adverse effect on the Company’s business, financial condition and operating results.

ITEM 1A. RISK FACTORS

Investors should carefully consider the risks in the “Risk Factors” in Part 1: Item 1A of our Annual Report on Form 10-K for the year ended December 31, 2023, filed with the SEC on April 11, 2024, and our other filings with the SEC. These risks are not the only ones facing the Company. Additional risks not currently known to us or that we currently believe are immaterial may also impair our business operations. Any of these risks could adversely affect our business, cash flows, financial condition, and results of operations. The trading price of our common stock could fluctuate due to any of these risks, and investors may lose all or part of their investment. In assessing these risks, investors should also refer to the other information contained or incorporated by reference in this Quarterly Report on Form 10-Q. There have been no material changes in our risk factors from those discussed in our Annual Report on Form 10-K for the year ended December 31, 2023.

ITEM 2. UNREGISTERED SALES OF EQUITY SECURITIES, USE OF PROCEEDS, AND ISSUER PURCHASES OF EQUITY SECURITIES

None.

ITEM 3. DEFAULTS UPON SENIOR SECURITIES

None.

ITEM 4. MINE SAFETY DISCLOSURES

Not applicable.

ITEM 5. OTHER INFORMATION

Rule 10b5-1 Trading Arrangement

During the three months ended September 30, 2024, no director or officer of the Company adopted or terminated any “Rule 10b5-1 trading arrangement” or “non-Rule 10b5-1 trading arrangement,” as each term is defined in Item 408(a) of Regulation S-K.

47

Table of Contents

ITEM 6. EXHIBITS

Exhibit Number |  | Description
10.1 |  | Elizabeth Alcaine Independent Director Agreement (incorporated by reference from Exhibit 10.1 to the Current Report on Form 8-K filed with the SEC on October 4, 2024).
31.1 |  | Certification of Principal Executive Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
31.2 |  | Certification of Principal Financial Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
32.1 |  | Certifications of Principal Executive Officer and Principal Financial Officer pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.
101.INS |  | Inline XBRL Instance Document - the instance document does not appear in the Interactive Data File because its Inline XBRL tags are embedded within the Inline XBRL document.
101 |  | The following financial statements from the Company’s Quarterly Report on Form 10-Q for the quarter ended September 30, 2024, formatted in Inline XBRL: (i) Condensed Consolidated Balance Sheets, (ii) Condensed Consolidated Statements of Comprehensive (Loss) Income, (iii) Condensed Consolidated Statements of Stockholders’ Equity, (iv) Condensed Consolidated Statements of Cash Flows and (v) Notes to Condensed Consolidated Financial Statements, tagged as blocks of text and including detailed tags.
104 |  | Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101).
* |  | Portions of this document have been omitted because they are not material and are the type that the Company treats as private and confidential.

48

Table of Contents

SIGNATURES

In accordance with the requirements of the Exchange Act, the registrant caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

Dated: November 13, 2024 | NEXTPLAT CORP
| By: | /s/ Charles M. Fernandez
|  | Charles M. Fernandez
|  | Chairman and Chief Executive Officer
|  | (Principal Executive Officer)
|  | /s/ Cecile Munnik
|  | Cecile Munnik
|  | Chief Financial Officer
|  | (Principal Financial Officer)

49